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Proteins participate in most of the important processes in cells, and their ability to
perform their function ultimately depends on their three-dimensional structure. They
usually act in these processes through interactions with other molecules. Because of the
importance of their role, proteins are also the common target for small molecule drugs
that inhibit their activity, which may include targeting protein interactions. Under-
standing protein interactions and how they are affected by mutations is thus crucial for
combating drug resistance and aiding drug design.
This dissertation combines bioinformatics studies of protein interactions at both pri-
mary sequence and structural level. We analyse protein–protein interactions through
linear motifs, as well as protein–small molecule interactions, and study how mutations
affect them. This is done in the context of two systems. In the first study of drug resis-
tance mutations in the protease of the human immunodeficiency virus type 1, we success-
fully apply molecular dynamics simulations to estimate the effects of known resistance-
associated mutations on the free binding energy, also revealing molecular mechanisms
of resistance. In the second study, we analyse consensus profiles of linear motifs that
mediate the recognition by the mitogen-activated protein kinases of their target proteins.




Proteine sind an den meisten wichtigen Prozessen in Zellen beteiligt, und ihre Fähigkeit,
ihre Funktion zu erfüllen, hängt letztlich von ihrer dreidimensionalen Struktur ab.
In diesen Prozessen wirken sie normalerweise durch Wechselwirkungen mit anderen
Molekülen. Aufgrund der Bedeutung ihrer Rolle sind Proteine auch die häufigsten An-
griffspunkte für niedermolekulare Wirkstoffe, die ihre Aktivität hemmen. Dies kann das
Targeting von Proteinwechselwirkungen umfassen. Um Wechselwirkungen mit Medika-
menten zu bekämpfen und das Wirkstoffdesign zu unterstützen, ist es wichtig, die Wech-
selwirkungen zwischen Proteinen und deren Einfluss auf Mutationen zu verstehen.
Diese Dissertation kombiniert bioinformatische Studien zu Proteinwechselwirkun-
gen sowohl auf primärer als auch auf struktureller Ebene. Wir analysieren
Protein-Protein-Wechselwirkungen anhand linearer Motive sowie Protein-Kleinmolekül-
Wechselwirkungen und untersuchen, wie sich Mutationen auf sie auswirken. Dies wird
untersucht im Kontext von zwei Systemen. In der ersten Studie zu Resistenzmutationen
in der Protease des humanen Immundefizienzvirus Typ 1 haben wir molekulardynamis-
che Simulationen erfolgreich eingesetzt, um die Auswirkungen bekannter Resistenz-
assoziierter Mutationen auf die freie Bindungsenergie abzuschätzen und molekulare Re-
sistenzmechanismen aufzuzeigen. In der zweiten Studie analysieren wir Konsensusprofile
von linearen Motiven, die die Erkennung der Zielproteine durch die Mitogen-aktivierten
Proteinkinasen vermitteln. So gewinnen wir Einblick in die zellulären Prozesse, an denen
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After observing the consistency of the amount of nuclear DNA in all the cells in all the
individuals for a given animal species, it was suggested that DNA and not the protein is
the underlying substance of genes (R. Vendrely and C. Vendrely 1948). Lack of correla-
tion between the amount of this DNA (C-value) and the presumed organism complexity
was later referred to as C-value paradox (Thomas Jr 1971), which was then resolved
by the discovery of the non-coding DNA. Sequencing of human genome, however, indi-
cated an unexpectedly small number of protein-coding genes and domains (International
Human Genome Sequencing Consortium 2001; Rubin 2001). This apparent lack of re-
lationship between the genes and organism complexity was then termed the G-value
paradox (M. W. Hahn and Wray 2002). Proteins, however, rarely act alone and usually
play a role in protein–protein interaction networks or complexes (Cusick et al. 2005).
Thinking in terms of electric circuits, it is possible to build a large variety of differ-
ent electric circuits using only a limited number of electronic components; it is in the
same way by combining different proteins and/or protein domains that a phenotypic
complexity and diversity can arise in biology (Bhattacharyya et al. 2006). Such modu-
lar approach is particularly suited for protein signalling networks (Cusick et al. 2005).
Some of the underlying biological techniques for modularity in such networks include
docking1, modular interaction domains, and scaffold or adapter proteins, as well as their
combinations (Figure 1.1). All of these protein–protein interactions refer to physical en-
counters between the underlying three-dimensional structures of these molecules. There
is however a wide spectrum of variety of the interfaces facilitating these interactions,
ranging from coming together of rigid domains, unstructured linear motifs that may ac-
quire secondary conformation only upon binding to its structured partner, or even cases
where both interfaces lack rigid structure (Davey et al. 2012). Mitogen-activated protein
kinase (MAPK), a broadly used enzyme for signalling in eukaryotes, is an example of a
protein that uses docking with an unstructured linear motif to facilitate its interactions.
Due to the central role of proteins in the cellular processes, in the vast majority of the
cases they are the target of pharmaceutical drugs (R. Santos et al. 2016). Kinases is one
class of proteins which are targeted by a rapidly growing number of inhibitors. One of
the most widely pharmaceutically targeted pathogens, Human Immunodeficiency Virus
type 1 (HIV-1), can be considered both one of the success stories in medical treatment
in terms of combating its pathogenicity (Antiretroviral Therapy Cohort Collaboration
2017), and arguably one of the first widely used applications of personalised medicine
(Lengauer et al. 2014). Both of these factors are the result of HIV-1 being the first viral
disease with a large number of different therapy options available (Palella et al. 1998).
Indeed, multiple classes of drugs against HIV-1 include those targeting different HIV-1
proteins and their different interaction mechanisms with other molecules: binding to the
active site, to the allosteric site restricting their conformational flexibility, or even using
1 As per (Bhattacharyya et al. 2006), in the context of this dissertation, docking refers to interaction of




Figure 1.1: Different enzyme-protein interaction modes. Adapted from (Bhattacharyya
et al. 2006) and reprinted, with permission, from Annual Reviews ©2006.
their catalytic reaction to cause chain termination. However, through mutation and
resulting changes in protein, HIV-1 is able to develop resistance towards all treatment
options, forcing changes in therapy. While expert knowledge-based mutation tables and
algorithms for resistance detection, as well as statistical analysis of clinical data aids
optimizing the therapy for individual patients (Lengauer et al. 2014), it does not broaden
our understanding of resistance in the molecular terms at the protein level. Analysing
protein–drug interactions, structural and energetic changes induced by mutations would
aid drug development against HIV-1, potentially opening a door to development of new
drugs or whole new drug classes (Hwang et al. 2017; Markham 2018).
Dissertation Scope and Outline
This dissertation comprises a collection of studies performed using structure- and
sequence-based approaches to analyse protein–protein and protein–drug interactions,
in particular, a study of HIV-1 protease drug resistance and MAPK docking interac-
tions. Chapter 2 first introduces the chemical theory on enzyme kinetics necessary for
understanding the inhibition of HIV-1 protease by antiviral drugs. The background of
HIV epidemic is then introduced, the structure of its viral particle, replication, as well as
treatment options and resistance, with a focus on the protease in the latter. The second
part of Chapter 2 describes phosphorylation and its biological function, with a focus on
MAPKs, their role in the signalling networks of the cell, and docking as a mechanism
they use for specific recognition of other proteins.
3
Chapter 3 introduces the experimental techniques used for protein identification, re-
solving their three-dimensional structures, measuring their enzymatic activity, as well
as resistance towards inhibitors, with more emphasis on techniques underlying acquiring
of data used in the present study. Computational techniques based on these data used
for analysing drug resistance upon mutations in the HIV-1 protease are then introduced.
Sequence-based computational techniques used for identifying the interaction partners
of MAPK are shortly discussed in Chapter 5 where the reader is referred to relevant
literature.
Chapter 4 describes a study we performed on HIV-1 protease drug resistance. For
this, computational techniques related to molecular dynamics simulations are used to
estimate the effect of various major resistance-associated mutations on the free energy of
binding of protease inhibitors. Then these computational estimations are compared to
different experimental measurements of the same phenomena. The effect of mutations
on the energetics of protein–drug interactions, as well as on the structure of the protein
are then analysed to gain insight on the resistance in molecular terms.
Chapter 5 describes our study of MAPKs’ interactome based on an analysis of docking
interactions through peptides called D-motif. Several different classes of linear motifs
mediating these interactions of MAPKs are identified based on a combination of evo-
lutionary and structural considerations. Different methods are applied to train models
for different classes of known or experimentally-identified D-motifs, as well as their or-
thologs, and then used to predict specific interactions in the MAPKs’ interactome and
gain insight in the associated functional processes and pathways. In a separate study of
interactions mediated by linear motifs, peptides targeted by proline-guided kinases, such
as MAPK, are grouped in order to find classes of potential downstream interactors.
Finally, Chapter 6 concludes this dissertation by summarizing the results of this work




In this chapter we present the background for the studies reported in this dissertation.
Section 2.1 introduces the theory of the enzyme kinetics and inhibition which is neces-
sary to understand the methods used for the resistance factor prediction of HIV type 1
protease. This section also introduces the acid disassociation constant relevant for the
protonation state of the active site of HIV-1 protease. The following Sections 2.2 and
2.3 introduce the biological background of HIV and the MAPK signalling.
Descriptions of the theoretical foundations follow in argument and
in notation (Copeland 2000) and (Copeland 2013) (Section 2.1) and
(Schmitt 2005) (Section 2.1.1).
2.1 Enzyme Kinetics and Inhibition
An enzymatic reaction starts with an encounter between an enzyme E and a substrate





with the reaction governed by a pseudo-first-order association constant kon and a first-
order dissociation constant koff . The equilibrium of the reaction by which complex ES









where [E] f refers to the molar concentration of the unbound enzyme ([E] f = [E]− [ES]),
and [S] is considered to approximate the free substrate concentration at saturating sub-





Once the complex ES is formed, the substrate is transformed by the enzyme active
site to a product P. This reaction is modelled in terms of a catalytic rate (also called






The velocity of such reaction, or reaction rate v, is derived in terms of velocity of the








6 2 BIOLOGICAL BACKGROUND
At infinite [S], one can define the maximum reaction velocity Vmax:
Vmax = kcat[E]. (2.4)




















. By setting the system in such a way that [S] equals Km, one can
consider Km as the substrate concentration that provides a reaction velocity of half of
the maximal velocity under conditions when the system is saturated with substrate.
In the presence of an enzyme inhibitor I with disassociation constant Ki, the enzyme














where constant α defines the degree to which I modulates the affinity of the enzyme to
the substrate. If the inhibitor has no effect on the ES complex formation, then α = 1,
whereas if it excludes its formation α = ∞. The latter class of inhibitors is referred to as
competitive inhibitors. The values of α between 1 and ∞ lead to formations in the ESI
complex, albeit at a slower rate, a process that is referred to as partial inhibition. While
partial inhibitors are known, the majority of therapeutically-used enzyme inhibitors at
saturating concentrations disrupt the activity of the enzyme completely.
Screening assays for enzyme targets can be used to measure the potency of different
enzyme inhibitors from the so-called progress curves. In such a curve, one measures over
time (x axis) the concentration of the product in moles (y axis). In the absence of the
inhibitor, the velocity of the enzymatic reaction v0 is defined by the slope of the progress
curve. The velocity of this reaction in the presence of a fixed concentration of inhibitor
[I] is denoted by vi. The remaining enzymatic activity at a fixed inhibitor concentration
is then given by the ratio vi
v0
and is termed the fractional activity. A typically used
measure of inhibitor potency, the Inhibitor Concentration required to reduce enzymatic
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where [S] is a fixed substrate concentration and [E]T is the total enzyme concentration.
For most protein–ligand binding interactions, the inhibitor concentration required to
achieve 50% inhibition of the enzyme far outstrips the enzyme concentration, meaning
that the amount of inhibitor sequestered by forming the EI complex is just a small
fraction of the total concentration of I. This renders [E]T in Equation 2.8 negligible,









Importantly in thermodynamic terms, Ki can be converted to the change in Gibbs free
energy:
∆G = RT ln Ki, (2.10)
where R is the ideal gas constant (it can also be expressed as R = kβNA, with kβ
denoting the Boltzmann constant and NA the Avogadro constant) and T is the absolute
temperature.
In thermodynamics, the change in Gibbs free energy is typically defined in the following
way:
∆G = ∆H − T∆S, (2.11)
where ∆H is the change in enthalpy and ∆S is the change in entropy.
The reaction rate can also be defined in terms of the enthalpy change in the system.
Namely, the heat change in system Q during a catalytic reaction is related to the con-
centration of product [P] generated and the molar enthalpy of the following reaction
(Mazzei et al. 2014):
Q = n∆H = V∆H[P], (2.12)
where n is the number of moles of product generated and V is the total volume. The










This relation is used to determine the kinetic parameters of reaction using Isothermal
Titration Calorimetry (ITC) (see Section 3.1.2).
2.1.1 Acid Disassociation Constant
Acids and bases can modulate the equilibrium of water self-ionization:
H2O+ H2O H3O+ + OH−.
By Brønsted’s definition acids are proton donors, while bases are proton acceptors, giving
the following acid-base equilibrium expression:
AH + B A− + BH+.
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Through proton donation acid AH becomes a conjugated base A− and through proton
acceptance base B becomes a conjugated acid BH+. In case of strong bases, such as
sodium hydroxide (NaOH), solvent molecules are forced to donate a proton; in case of
strong acids, such as hydrochloric acid (HCl), almost every hydrochloric acid molecule
donates to the solution its proton. In case of weak bases and acids a “real” equilibrium
exists between acid and base, or conjugated base and conjugated acid.
Functional groups of organic molecules are often weak bases or acids. So carboxyl
groups (R-COOH) can donate their proton to make a carboxylate group (R-COO−),
while the base amino group (R-NH2) can accept a proton to become ammonium ions








where in case of Ka the concentration of H2O is considered to be almost unchanged. The
negative logarithm − log Ka of this dissociation constant is referred to as pKa. Thus,
pKa measures the strength of the acid, with a low pKa value corresponding to a strong
acid. If the proton concentration in the aqueous solution, pH, equals pKa, then acid and
conjugated base are present in equal concentration. By increasing pH, an acid will turn
into a conjugated base.
Description of the biological foundations in Section 2.2 are partly
adapted from (Bastys 2012).
2.2 Human Immunodeficiency Virus
2.2.1 General Information
Human Immunodeficiency Virus is a retrovirus that causes Acquired Immunodeficiency
Syndrome (AIDS), a condition in which a dysfunctional immune system is unable to
cope with opportunistic infections and cancer. The virus was first discovered in the
early 1980s and is thought to have originated from a transmission from non-human pri-
mates to humans (Sharp and B. H. Hahn 2011; Faria et al. 2014). Currently it infects
36.7 million people with 1.8 million new infections per year (Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) 2017b). The infections occur through transmission
of bodily fluids, primarily being sexually transmitted (Rom and Markowitz 2007). HIV
compromises the human immune system by infecting helper T-cells (cluster of differen-
tiation 4 (CD4)+ type), macrophages, and dendritic cells, eventually leading to their
destruction.
2.2.2 Subtypes
Two types of HIV are currently recognised: HIV-1 and HIV-2. The Simian Immun-
odeficiency Virus (SIV) infecting the chimpanzee subspecies Pan troglodytes troglodytes
(SIVcpz) is considered to be the source of HIV-1 and gorilla SIV (SIVgor) through cross-
species transmission (Keele et al. 2006; Van Heuverswyn et al. 2006). SIVsmm, infecting
sooty mangabey (Cercocebus atys atys), is thought to be the source of HIV-2 (Hirsch
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Figure 2.1: A phylogenetic tree showing relationship between SIVcpz, HIV-1, and SIV-
gor. SIVcpz sequences are depicted in black, SIVgor in green, and HIV-
1 in the other colours respectively. Black circles reflect cross-species
transmission-to-humans and white circles reflect two possible alternative
branches for chimpanzee-to-gorilla transmission. Question mark indicates
SIVgor as likely source of HIV-1 groups O and P, with particularly strong
evidence for the former (D’arc et al. 2015). Adapted from (Sharp and B. H.
Hahn 2011) and reprinted, with permission, from Cold Spring Harbor Lab-
oratory Press ©2011.
et al. 1989). Of the two types of HIV, HIV-2 is considered to be a lesser health hazard
as it accounts for fewer infections worldwide (World Health Organization 2016), as well
as it has lower transmission rate and pathogenicity (Kannangai et al. 2012).
HIV-1 is divided into groups M, N, O, and P, all of which are thought to have originated
from separate introductions of SIVcpz and SIVgor into the human population (Gao et al.
1999; Plantier et al. 2009; Vallari et al. 2011; D’arc et al. 2015) (Figure 2.1). Group
M is estimated to account for the vast majority of all HIV infections in humans (A. F.
Santos and Soares 2010; Hemelaar 2012). Based on the genetic variation within the
M group, the group is further divided into subtypes: A, B, C, D, F, G, H, J, K and
their hybrids called Circulating Recombinant Forms (CRFs). A commonly used HIV-1
reference sequence called HXB2 is from group M subtype B. From here on we will refer
to HIV-1 as HIV.
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Figure 2.2: HIV genome structure. Adapted from (Los Alamos National Laboratory
2017).
2.2.3 Genome and Viral Particle Structure
The HIV particle is about 120 nm in diameter. It consists of 15 types of proteins
and a genome coding Ribonucleic Acid (RNA) of approximatively 9700 bp length (Fig-
ure 2.2). HIV proteins can be roughly divided into three groups: structural, enzymatic,
and accessory proteins (Frankel and J. A. Young 1998). Some of these proteins are
expressed as polyproteins and are cleaved by the HIV protease during the virus mat-
uration. The structural proteins are: (i) four proteins from the group-specific antigen
(gag) polyprotein: matrix (MA), capsid (CA), nucleocapsid (NC), and p6; and (ii) the
two proteins from the envelope (env) polyprotein: glycoprotein 120 (gp120) and glyco-
protein 41 (gp41). Together these proteins make up the virus capsid and, along with a
portion of the lipid membrane borrowed from the host cell, the viral envelope. Proteins
from the polymerase (pol) polyprotein, protease (PR), reverse transcriptase (RT), and
integrase (IN), are responsible for the enzymatic functions in the virus. The rest of
the proteins, negative regulatory factor (Nef), regulator of expression of virion proteins
(Rev), trans-activator of transcription (Tat), virion infectivity factor (Vif), viral protein
R (Vpr), and viral protein U (Vpu), perform various auxiliary functions throughout the
HIV replication cycle. At both ends of the viral RNA, there are the long terminal repeats
(LTRs), which include transcription promoters.
2.2.4 Replication Cycle
The first step performed by HIV to enter into its target cell is through interaction with it
via binding of the viral protein gp120 to the CD4 receptor protein and coreceptors C-C
chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) of the
target cell. The preference of HIV to bind to a certain type of coreceptor depends on the
strain of the virus and is called viral tropism. Subsequently, a conformational change
in another envelope protein, gp41, induces fusion of the membranes of the virus particle
and host cell. Then the virion core is uncoated, exposing viral RNA. With the help of
RT, RNA is reversely transcribed to Deoxyribonucleic Acid (DNA), a double-stranded
version of which is transported to the cell nucleus with MA mediating the process (Gallay
et al. 1995). In the nucleus it is then integrated into the DNA of the host cells by IN.
A copy of the viral genome can reside dormant in a host cell for a long time. At
the next active stage of the virus replication cycle, viral genome is transcribed from
its integrated copy in the host DNA with the help of promoters residing in LTR, with
Tat protein enhancing the process (Kao et al. 1987; Roy et al. 1990). At this stage, a
set of both spliced and full-length RNAs is transported from the host nucleus to the
cytoplasm, a development controlled by Rev protein (Hope 1999). The viral Messager
RNA (mRNA) is then transcribed in the cytoplasm, and a new viral particle starts to
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Figure 2.3: HIV life cycle. Taken from (National Institute of Allergy and Infectious
Diseases 2010).
form: gag polyproteins associate with the inner membrane side and the env polyproteins
anchor to the outer membrane and transmembrane regions after the degradation of
CD4+ receptors (carried through by proteins Vpu and Nef) (Bour et al. 1995). The viral
RNA is brought to the assembling virion by NC. After the virus particle has finished
forming, it buds from the cell. During the budding process, Vif protein protects the virion
by inhibiting the viral genome hypermutation-inducing human protein, apolipoprotein B
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mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G), from entering the
particle (Stanley et al. 2008; Henriet et al. 2009). At the same time and also later as a
free particle, the virus undergoes a maturation process, where gag and pol polyproteins
are cleaved by PR. At this stage the capsid forms from CA proteins within the virion
protecting its genome.
2.2.5 Treatment and Drug Resistance
Despite some promising recent advances in the development of vaccine against HIV
(Barouch et al. 2018), there is currently no licensed vaccine for it. Pre-Exposure Pro-
phylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) are recommended for people
with substantial risk of HIV infection, and Antiretroviral Therapy (ART) is recom-
mended for every infected individual to suppress the virus (World Health Organization
2016). Antiretroviral (ARV) drugs are divided into several categories roughly based on
the stage of replication cycle or the part of virus that they target. Since the drugs have
different targets and act at different stages of the HIV replication cycle, it is possible
to use them in combinations. Except for select few individual cases (Allers et al. 2011;
Jessen et al. 2014), with no cure available ART remains the only means to combat the
virus, leading to near-normal life expectancy of the HIV-infected patients (Antiretroviral
Therapy Cohort Collaboration 2017).
In the following, we discuss the action mechanisms of the U.S. Food and Drug Ad-
ministration (FDA)-approved inhibitors action.
Entry Inhibitors
Entry inhibitors target the interactions of gp120 and gp41 proteins with the cell. The
drug maraviroc binds to the hydrophobic pocket of the CCR5 receptor, which is believed
to change the conformation of the extracellular loops of CCR5, restricting the interaction
of gp120 with this receptor (Tilton and Doms 2010). On the other hand, enfuvirtide,
a biomometic peptide, is a competitive binder to the heptad-repeat domain 1 of the
gp41 (Tilton and Doms 2010). Disrupting the proper arrangement of the domains of
gp41 precludes the fusion of the viral particle with the cell’s membrane. The latest
drug to be approved for ART, ibalizumab, is from a subcategory of entry inhibitors,
namely post-attachment inhibitors (Markham 2018). It binds to the domain 2 of CD4
receptor of the human cell which, while allowing for binding of receptor with gp120,
induces structural changes prohibiting the interaction of gp120 with both CCR5 and
CXCR4 coreceptors (S. A. Iacob and D. G. Iacob 2017). Thus, the main advantage of
ibalizumab in comparison to maraviroc is that the latter is only effective against CCR5-
tropic viruses, whereas the former can potentially target both gp120-tropicity variants.
Nucleoside and Nucleotide Reverse-Transcriptase Inhibitors
Nucleotide or Nucleoside Reverse-Transcriptase Inhibitors (NRTIs) are historically the
first FDA-approved drugs against HIV (Antiretroviral Drugs Used in the Treatment of
HIV Infection n.d.). They compete with the natural Deoxynucleoside Triphosphates
(dNTPs) for incorporation by RT in the viral DNA (Cihlar and Ray 2010). NRTIs,
despite their structural diversity, all mimic the structural contacts of the natural dNTP
in the RT active site. Once they are incorporated into the DNA, because they lack
3’-hydroxl, no further nucleotides can be incorporated, and thus the DNA synthesis is
terminated.
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Non-Nucleoside Reverse-Transcriptase Inhibitors
Like NRTIs, the Non-Nucleoside Reverse-Transcriptase Inhibitors (NNRTIs) also in-
terfere with the reverse transcription process. However, they bind to the RT itself,
specifically to the hydrophobic pocket close to the active site of the polymerase (the
so-called NNRTIs binding pocket). While the exact molecular mechanism of action is
not clear, it is thought that the structural changes induced by this binding reduce the
catalytic activity of RT (Sarafianos et al. 2009).
Integrase Strand-Transfer Inhibitors
The Integrase Strand-Transfer Inhibitor (INI) targets the next stage of the HIV replica-
tion cycle, namely the incorporation of viral DNA into the host cell’s genome. Due to
the complexity of this reaction, as well the fact that only two such integration events per
50–100 copies of IN present in the host cell after infection are sufficient for production of
provirus, INIs were historically the last category of ART drugs to be approved. Indeed,
binding of INI to the active site of IN is not well understood, but it has been suggested
that viral DNA might be part of the IN binding site (McColl and X. Chen 2010). By
chelating the metal ions in the active site of IN INIs inhibit the catalytic activity of the
enzyme.
Protease Inhibitors
Protease Inhibitors (PIs) were an early-developed class of ARV drugs for HIV treatment.
This class of drugs targets the maturation of the virus, specifically the PR enzyme. The
two active site aspartic acids in the substrate binding pocket of PR, which is a symmetric
dimer, cleave the gag and gag-pol polyproteins of the virus. These polyproteins have dif-
ferent residues around the cleavage sites, so it has been suggested that PR recognises the
asymmetric shape of the peptide rather than the exact sequence itself (Prabu-Jeyabalan
et al. 2002). All PIs competitively bind in the substrate binding pocket of PR. With
the exception of Tiprananavir (TPV), which has a dihydropyrone ring at its core, they
are all peptidomimetic and have a hydroxyethylene core to protect them against the
cleavage by PR (Wensing et al. 2010) (Figure 2.4). Inhibitor Amprenavir (APV), which
has previously been aproved by FDA, is no longer marketed as it has been replaced by
its prodrug Fosamprenavir (FPV), meaning FPV gets metabolized in the body to APV.
Drug Resistance
Due to the high mutation rate of HIV, reported to be in the range of 1.2 − 3.4 × 10−5
(Mansky and Temin 1995; Abram et al. 2010), resistance due to mutation in the HIV
genome is one of the major issues in HIV treatment issues. Human Immunodeficiency
Virus Drug Resistance (HIVDR) mutations can occur de novo or they can be trans-
mitted during the infection. With over half of the infected individuals receiving ART
(Joint United Nations Programme on HIV/AIDS (UNAIDS) 2017a), the latter source for
HIVDR is becoming more prevalent with a recent World Health Organization (WHO)
report suggesting over 10% of pretreatment HIVDR to NNRTIs in 6 out of 11 surveyed
countries (World Health Organization 2017). Drug resistance is a relevant issue for all
ART drugs classes. For the competitive inhibitors, Resistance-Associated Mutations
(RAMs) can either unfavourably affect the binding affinity of the inhibitors, or improve
the fitness of the virus. In case of PIs, the first category has been referred to as primary




Figure 2.4: HIV PIs analysed in this dissertation. Figure taken from (Bastys et al.
2018).
mutations, and the second category of mutations is called compensatory mutations, as
they act to compensate the negative effect of primary mutations on the catalytic activity
of the protein (Henderson et al. 2012).
In line with PIs binding in the substrate binding pocket of protease (further referred to
as protease binding pocket), most of the major RAMs towards PIs appear in the different
structural elements composing the binding pocket (Figure 2.5). This includes the active
site loop (residues D30, V32, and L33), the so-called 80s loop (residues V82 and I84) —
both forming the sides of the pocket, or the flap region of the protease (residues M46,
I47, G48, I50, and I54). Yet several RAMs are also found at sites that are distant to
the binding pocket sites, e.g. residues N88 and L90 in the protease’s α-helix or residue
L76 in the hydrophobic core. Hence, the effect of these mutations on inhibitor binding
is likely to be not through direct interactions.
Descriptions of the biological foundations in Section 2.3 are partly
adapted from (Bastys 2012).
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Figure 2.5: HIV protease structure. The flap region is depicted in cyan, 80s loop
in brown, active-site proximate loop in olive colours. Major resistance-
associated mutation sites (red), catalytic site residues (blue), and bound
inhibitor (magenta) are shown in sticks model.
2.3 Mitogen-Activated Protein Kinases
2.3.1 Protein Phosphorylation
Post-Translational Modification (PTM) is a modification of a standard amino acid by a
covalently bound chemical group. Although present in most organisms, it is by far more
wide-spread in higher eukaryotes, in which estimated 5% of the genome is dedicated to
enzymes carrying out PTMs (Walsh et al. 2005). PTMs are, for example, employed in
signalling cascades that transmit signals from extracellular stimuli to the nucleus, thus
contributing to a higher complexity of these organisms (Deribe et al. 2010).
The most prevalent PTM is phosphorylation (Khoury et al. 2011). It is estimated
that between one- and two-thirds of all proteins in a typical mammalian cell may be
phosphorylated (S. A. Johnson and Hunter 2005; Vlastaridis et al. 2017). During phos-
phorylation, a phosphate group (PO4) from a high energy donor molecule (such as
Adenosine Triphosphate (ATP)) is transferred to a substrate protein and bound cova-
lently to an amino acid. In case of eukaryotes, primarily serine, threonine, or tyrosine can
be phosphorylated, typically by a dedicated enzyme called kinase, whereas in prokary-
otes a two-component signalling, involving histidine kinase and regulator protein, is
most common (Stock et al. 2000). Protein phosphorylation has been suggested to have
diverse effects on the protein structure. An early comparative study on the effect of
phosphorylation for more than a dozen different proteins suggested as the main effect
of phosphorylation to be a change in protein conformation to accommodate the elec-
trostatic effects of the phosphate (L. N. Johnson and Lewis 2001). However, a later
large scale study on phosphorylation effects suggested that in most cases changes in
the protein structure upon phosphorylation are modest, as in only 13% of the cases the
comparison of phosphorylated and unphosphorylated forms of protein exhibited changes
> 2 Å in root mean square deviation (Xin and Radivojac 2012). Phosphorylation can
also induce large structural effects indirectly, such as the phosphorylation site being
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recognized by an enzyme which then triggers a conformational switch (Lu et al. 2002) or
phosphorylation acting as an allosteric effector through which local changes propagate to
larger tertiary ones (Nussinov et al. 2012). Another observed effect of phosphorylation
was modulating the disorder-to-order transitions (Nelson et al. 2005).
Among other roles of phosphorylation, its importance in affecting protein–protein
interactions is corroborated by the tendency of the phosphorylated sites to be found
on the protein–protein interaction interfaces (Nishi et al. 2011). The conservation of
phosphorylated residues in these interfaces is also higher than that of other residues.
It has also been reported that of the residues found on the binding interfaces, serine,
threonine, and tyrosine from the disordered regions of the interface tend to be more
frequently phosphorylated compared to the same residues from the ordered interfaces
(Nishi et al. 2013). This is in line with the overall tendency of disordered regions of
proteins to be enriched in phosphorylation sites (Iakoucheva et al. 2004; Gsponer et
al. 2008; Singh 2015). If multiple phosphorylation sites are found in a protein, they
tend to be clustered in the same region of the protein (H. Li et al. 2009; Schweiger
and Linial 2010; Freschi et al. 2014), with the majority of the serine and threonine
phosphosites (phosphorylation consensus sequences) found within four residues of each
other (Schweiger and Linial 2010). Co-occurance of multiple phosphorylation sites can
play a role in increasing the binding affinity of the protein interactions (Ferreon et al.
2009) and the accuracy of the conformational change modulation (Kumar et al. 2012).
2.3.2 Mitogen-Activated Protein Kinases Signalling
Over 500 kinases have been identified in the human genome (Manning et al. 2002).
With a few exceptions (Dhanasekaran and E. P. Reddy 1998; Fuhs and Hunter 2017),
mammalian kinases are split into serine/threonine kinases and tyrosine kinases groups.
Mitogen-activated protein kinases (MAPKs) are a family of serine/threonine kinases that
are broadly spread and well conserved in eukaryotes. The divergence of two of the MAPK
subgroups, extracellular signal-regulated kinase (ERK)-like and p38 mitogen-activated
protein kinase (p38)-like, pre-dates the divergence of animals and fungi as proven by
the existence of Fus3 (ERK-like) and Hog1 (p38-like) yeast kinases (Good et al. 2009;
Duch et al. 2012). The animal-specific MAPK subgroups—mitogen-activated protein
kinase 3 (ERK1)/mitogen-activated protein kinase 1 (ERK2), mitogen-activated protein
kinase 7 (ERK5), c-Jun N-terminal kinases (JNKs), p38s—appear early in the metazoan
evolution, as these kinases can be found in choanoflagellates, sponges, and cnidarians
(King et al. 2008; Chera et al. 2011).
With the exception of the “atypical” MAPKs, such as mitogen-activated protein kinase
6 (ERK3), mitogen-activated protein kinase 4 (ERK4), mitogen-activated protein kinase
15 (ERK7), and nemo-like kinase (NLK) (Coulombe and Meloche 2007), MAPKs usu-
ally form a three-tier cascade with two phosphorylation events, i.e. MAP3K–MAP2K–
MAPK. Here a mitogen-activated protein kinase kinase kinase (MAP3K) phosphorylates
a mitogen-activated protein kinase kinase (MAP2K), which eventually phosphorylates
a MAPK. These cascades can be initiated by diverse extracellular stimuli and result in
various cellular responses (Figure 2.6). ERK1 and ERK2 are mostly involved in cell
division (meiosis and mitosis) and cell differentiation. They are activated by a number
of diverse stimuli, which include growth factors, cytokines, viral infections, carcinogens,
ligands for G protein coupled receptors, and transforming agents (G. L. Johnson and
Lapadat 2002). Mitogen-activated protein kinase 8 (JNK1), mitogen-activated protein
kinase 9 (JNK2) and mitogen-activated protein kinase 10 (JNK3) are stress-activated
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Figure 2.6: MAPK activation cascades. Taken from (Wikipedia contributors 2018).
protein kinases. They were originally identified as phosphorylating the DNA-binding
protein c-Jun. JNKs have also been shown to participate in cell death (apoptosis) and
immune response by mediating T-cell differentiation, processes in which JNKs’ targets
include p53, Elk-1, and nuclear factor of activated T-cells 4 (NFAT4) (Vlahopoulos
and Zoumpourlis 2004). The p38 kinase group includes α, β, γ, and δ kinases, of which
mitogen-activated protein kinase 14 (p38α) is best characterised. Similarly to JNKs,
p38s are involved in apoptosis and immune response and their activating stimuli include
cytokines, hormones, ligands for G protein-coupled receptors, osmotic shock, and heat
shock (G. L. Johnson and Lapadat 2002). Studies of upstream JNK- and p38-activating
kinases have indicated an important role of both of these families in development of
various organs in animals (Ganiatsas et al. 1998; A. Pearlman et al. 2010; Le Goff et al.
2016; Spielmann et al. 2016; Wade et al. 2016). Because of similarity in the functions
of their pathways, some proteins (e.g. MKK4) have been suggested to directly interact
with both JNKs and p38s (Derijard et al. 1995). On the other hand, the protein deleted
in colorectal carcinoma (DCC) has been suggested to be involved in both JNK and ERK
pathways, albeit directly interacting only with the ERK (Arakawa 2004; Qu et al. 2013;
Ma et al. 2010). In vitro experiments have also indicated promiscuous interaction be-
tween peptides of MAP2Ks and both p38α and ERK2 (Garai et al. 2012) (see below).
Another ERK, ERK5, has been suggested to be involved in heart and vessel develop-
ment (Regan et al. 2002), with Mef2 proteins (e.g. myocyte-specific enhancer factor 2A
(MEF2A)) as some of its reported targets (Yang and Gabuzda 1998).
Target Recognition
Just like cyclin-dependant kinases (CDKs) and glycogen synthase kinase 3 (GSK3),
MAPKs are referred to as proline-directed kinases, since they have a preference for the
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Figure 2.7: A JNK1 structure (cyan) with two distinct docking groove regions, the CD
groove (blue) and the hydrophobic docking groove (light-brown), with a
bound D-motif peptide (black) and an ATP molecule (yellow) (Garai et al.
2012). Taken from (Zeke et al. 2015).
phosphorylated residue to be followed by a proline ([ST]P) (Lu et al. 2002). Due to
the frequency of such short consensus sequence in the proteome, additional mechanisms
have been suggested to ensure signal fidelity. In the case of ERK5, a mediation of the
interaction with its target protein by a separate domain has been observed (Glatz et al.
2013). Different sites on MAPKs and their targets, distant to both the active site and
the phosphoacceptor site respectively, were suggested to regulate the interaction (J. A.
Smith et al. 2000; Tanoue et al. 2001).
However, the best studied mechanism facilitating MAPK phosphorylation is through
interactions with peptide sequence on the target called D-motif (Sharrocks et al. 2000;
C.-I. Chang et al. 2002; Mooney and Whitmarsh 2003; Reményi et al. 2005; Ma et al.
2010; Garai et al. 2012; Glatz et al. 2013). Similar kind of interactions, referred to as
docking interactions or docking, have been reported for various other serine/threonine
kinases, such as CDKs, GSK3, and PDK1 (for review see (Biondi and Nebreda 2003))
but also for serine/arginine kinases, such as SRPKs (J. C. K. Ngo et al. 2005; Long
et al. 2018). D-motif, which typically resides in intrinsically disordered regions of the
target proteins (Neduva and Russell 2005; Garai et al. 2012), binds to the site of MAPK
composed of the so-called hydrophobic docking groove and CD groove, improving the
interaction between the two proteins (Figure 2.7). D-motifs could be described with a
common loosely-defined consensus: θ1−2x0−5ϕLx1−2ϕAxϕB, where ϕL, ϕA, and ϕB denote
positions that are typically filled by hydrophobic amino acids, with L, A, and B referring
to the lower pocket, and pockets A and B respectively, while θ denotes positively charged
(arginine or lysine) and x denotes any amino acid. During the interaction between the D-
motif and MAPK, the hydrophobic and charged part of D-motif bind to the hydrophobic
docking groove and CD groove, respectively.
“Reverse D-motifs” have also been suggested as binding mediators. They are similar
to D-motifs in that they use the same mechanism of interaction, but in them the motif
sequence is reversed compared to standard D-motif that runs from the N- to C-terminus
(Garai et al. 2012). However, only few such examples are known so far.
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Unlike for other motifs, such as FxFP which mediates binding with some MAPKs in
the so-called DEF groove and is typically located 10 residues away from the phosphoac-
ceptor site towards the C-terminus, the location of D-motifs is variable (Bhattacharyya
et al. 2006). Employment of D-motifs for interaction is not limited to MAPK tar-
gets, but D-motifs have also been suggested to mediate the interaction with MAPK
regulators, such as phosphatases (e.g. protein tyrosine phosphatase non-receptor type
7 (HePTP) (Zhou et al. 2006)), and MAP2Ks (Enslen et al. 2000; Garai et al. 2012),
as well as mediating assemblies of protein scaffold complexes (e.g. c-Jun-amino-terminal
kinase-interacting protein 1, also called MAPK8IP1 or JNK1 interacting protein 1 (JIP1)





This chapter introduces some experimental and computational techniques relevant for
the work presented in this dissertation. Section 3.1.1 discusses methods used for protein
structure identification, whereas Section 3.1.4 discusses the underlying assay used in per-
forming the experiments described in Chapter 5. Relevant to Chapter 4, the methods for
determining protein enzymatic activity, inhibition, and its drug resistance are discussed
in Sections 3.1.2 and 3.1.3, respectively. Finally, aspects relevant to the mutation mod-
elling in protease (Section 3.2.1), the determination of the reference protonation state of
its active site (Section 3.2.5), its simulation (Section 3.2.4), and the theory behind free
energy differences and their calculation (Sections 3.2.2 and 3.2.3) later used in Chapter
4 are presented.
Descriptions of experimental techniques foundations of X-ray Crys-
tallography follow in argument and in notation (Ilari and Savino
2008), Nuclear Magnetic Resonance Spectroscopy follows (Markley et
al. 2009), Cryo-TEM and Cryo-ET follows (Volkmann and Hanein
2009), and Section 3.1.2 follows (Copeland 2000), respectively.
3.1 Experimental Methods for Data Acquisition
3.1.1 Protein Structure Determination
X-ray Crystallography
Since resolving the crystal structure of myoglobin in 1957 (Kendrew et al. 1958), X-ray
crystallography has played the central role in structural biology. Close to 90% of all
the structures in the Protein Data Bank (PDB) have been resolved using this method
(Berman et al. 2000; PDB Current Holdings Breakdown n.d.), which is based on the
observation that atoms form a regular, repeating pattern within the crystals. When
stricken by X-rays, this allows for reading the diffraction pattern from the resulting
waves.
Protein sample preparation in X-ray crystallography requires the protein to be crystal-
lized, which is mainly a trial-and-error procedure. A highly purified protein is dissolved
in a solvent and the solution is then brought to supersaturation, during which time the
crystal nuclei can start to form, creating a basis from which the crystal can grow. When
X-rays are shone on the crystal, they are scattered by the crystal planes. Most of these
rays cancel out through destructive interference, but some of them add constructively
as defined by the Bragg’s law (W. H. Bragg and W. L. Bragg 1913). As a consequence
of this law, the wavelength of radiation must be similar to interatomic distances. The
21
22 3 EXPERIMENTAL AND COMPUTATIONAL TECHNIQUES
diffraction pattern of the crystal can be recorded on a photographic film or Charged-
Coupled Device (CCD) image sensor. To measure all the diffracted reflection intensities
of the crystal, the crystal is rotated during the image recording procedure. Then the
atom positions may be identified based on the distribution of electron density in the
diffraction pattern. This involves estimating the phase of the waves recorded in the pat-
tern (phase problem), which, under certain conditions, can be performed directly from
the recorded data or by fitting to a related structure.
X-ray crystallography suffers from a number of difficulties, primarily related to the
crystal preparation, but also their handling, collecting the diffraction patterns and their
interpretation. Because hydrogen atoms only have one electron, it is difficult to cap-
ture its density, thus hydrogen typically cannot be resolved by this technique. Neutron
diffraction, a related technique where neutrons are shot instead of X-rays, can alleviate
this, as they scatter from the nuclei, enabling to record the positions of hydrogen atoms
as well.
Nuclear Magnetic Resonance Spectroscopy
Nuclear Magnetic Resonance (NMR) spectroscopy, at approximately 9%, is historically
the second most used method for macromolecular structure determination. It can be
considered complementary to X-ray crystallography in that it can resolve structures
which are partially disordered, have multiple stable conformations or are not amenable
to crystallization. In NMR, transitions between the spin states of nuclei with magnetic
activity, e.g. (1H), (13C), and (15N), when placed in an NMR tube of an NMR spec-
trometer, are investigated. These stable isotopes have a nuclear spin of 12 and thus two
spin states: one paired with the external magnetic field and one opposing the external
field. The magnetic moment of each nuclei orients itself around the external magnetic
field, being also influenced by other magnetic fields, such as neighbouring spins in the
molecule and preprogrammed radio-frequency pulses of spectrometer. Applying these
pulses flips the magnetic spin of the nuclei, which induces an oscillating current, called
the free induction decay, in the coil that detects the signal (resonance). Fourier transfor-
mation of this time-domain signal converts it to frequency-domain signal, called NMR
peak. More complicated pulse sequences, i.e. from multiple orthogonal frequency axes,
allow for reading out multidimensional NMR spectra of the nuclei. Due to the spinning
effects of the neighbouring nuclei, the resonance of the nuclei deviates from a reference
frequency or a standard compound (e.g. tetramethylsilane, trimethylsilylpropanoic acid,
or 4,4-dimethyl-4-silapentane-1-sulfonic acid), called chemical shift. For proteins, this
is sufficient to provide reliable information about their secondary structure. Additional
structural restraints in NMR can be obtained from the so-called nuclear Overhauser
effect (nOe) spectrum (Overhauser 1953; Anderson and Freeman 1962), which provides
1H – 1H distance constraints, as well as empirical torsion angle constraints based on
chemical shifts.
NMR is considered to be applicable for high-throughput protein structure determi-
nation of proteins up to 25 kDa, as long as stable, soluble isotope-labelled samples can
be prepared. Because of the peak overlap that happens when different atoms have very
similar chemical shifts, as well as signal degeneracy, it is challenging to solve structures
of proteins larger than 40 kDa.
Since spin relaxation rates of nuclei are sensitive to protein motions, changes in protein
structure can also be captured in the NMR experiment. Hence, this allows for observing
the protein dynamics on a wide range of time scale.
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Cryo-TEM and Cryo-ET
Cryo Transmission Electron Cryomicroscopy (cryo-TEM) and cryo Electron Cryotomog-
raphy (cryo-ET) are related emerging techniques for protein structure solving. Some of
the restrictions on samples of X-ray crystallography and NMR techniques do not ap-
ply to these methods: the crystalline structure is not necessary, there is no upper size
limit, and small quantities are sufficient. The technique itself is very similar to standard
light microscopy, but here electrons are used which are of lower wavelength than light,
and thus enable for atomic resolution. Briefly, the beam of electrons is directed to the
specimen, which has been frozen to protect it from evaporation and radiation damage,
scattering some of the passing electrons which are then collected by a lens system and
focused to form first a diffraction pattern and then a photographic or CCD image. To
acquire a three-dimensional structure for a homogeneous specimen, averaging of thou-
sands of cryo-TEM images of different particles at different orientations is performed.
If a single structure is available, cryo-ET can be employed, where multiple images are
taken of the specimen as it is tilted over a wide range of angles, from which a structure
can be reconstructed. Due to the previously mentioned advantages of cryo-TEM and
cryo-ET, and because of their limited resolution, the greatest advantage of these tech-
niques was observed when used in combination with X-ray crystallography and NMR.
However, the resolution of structures resolved in these methods keeps improving, with
a 1.8 Å glutamate dehydrogenase, a hexamer, reported in recent studies (Merk et al.
2016). However, with these methods the higher resolution of the structures, like in the
case of the mentioned hexamer, is typically achieved by using the internal symmetry of
the underlying structure.
3.1.2 Enzymatic Activity Measuring
Most of the assays used to measure the velocity of the enzymatic reactions are performed
by one or more of the following methods: spectroscopy, calorimetry, polarography, ra-
dioactive decay, electrophoretic separation, chromatographic separation, or immunolog-
ical reactivity. These assays directly measure the substrate or product concentration in
the reaction as a function of time and thus can be referred to as direct assays. If a dis-
tinct signal from a reaction is not available, other, nonenzymatic reactions are coupled
to the product generation (indirect assays), or different enzymatic assays are combined
to create a coupled assay.
Assays Based on Optical Spectroscopy
Two of the most common means to measure enzymatic reaction are absorption spec-
troscopy and fluorescence spectroscopy. Changes in the electronic configuration of the
molecules as a result of them absorbing light energy of specific wavelengths is the under-
lying principle of these methods. When irradiating a molecule with varying wavelengths
of light, the wavelengths whose energy matches the energy gap between two electronic
states of the molecule will be strongly absorbed, inducing a transition between those
two states. Beer’s law (Beer 1852) relates this absorption A to the concentration of the
sample in molar units c, the length of the sample the light traverses l, and the so-called
molar absorptivity of the molecule ϵ. Thus, if ϵ is known, A can be determined from
the absorption spectroscopy experiment. When such an absorption causes the transition
between two electronic states of the molecule, the excited state is short-lived and the
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molecule returns to the ground state after emitting the excess energy through heat dis-
sipation or, in some cases, emitting a photon. This fluorescence maximum is of longer
wavelength (lower energy) than the absorption maximum, which is referred to as Stokes
shift. If the substrate–product pair is not naturally fluorescent, it is often possible to
covalently attach a fluorescent group without affecting the pair’s interaction. After mea-
suring at the same time fluorescence of both the target sample and a standard solution
(to avoid variance due to lamp intensity), comparing the two fluorescence curves provides
sensitive means to evaluate the concentration of the molecule.
Isothermal Titration Calorimetry
ITC is performed by a homonym device, whose main component is an adiabatic jacket
containing two cells connected to the outside by narrow tubes. One of these cells, the
sample cell, contains the solution, while the other, the reference cell, contains buffer or
water. A thermoelectric device measures the temperature of both cells and using a cell
feedback heater maintains them at equal temperature. By injecting the substrate into
the sample cell, the amount of heat released or absorbed is measured. By (i) injecting
the complete substrate to measure the total molar enthalpy ∆H and (ii) doing multiple
substrate injections at different concentrations the heat flow dQ/dt is measured in two
separate experiments, which allow to derive Km and Kcat.
The same procedure can be used to measure the binding affinities between different
molecules. The advantage of ITC is that by providing both Kd and ∆H measurements,
it enables the estimation of all the thermodynamic parameters of the Gibbs free energy
from Equation 2.11.
3.1.3 Phenotypic Viral Drug Resistance Testing
Historically, the first widely used HIV drug resistance tests employed Peripheral Blood
Mononuclear Cells (PBMCs) isolated from the patients. These are mixed with donor
PBMCs for cultivation and, after drug exposure, the antigen (typically Capsid protein
2.2.3) is measured (Mayers et al. 1992; Japour et al. 1993). This approach had several
disadvantages, being time consuming, difficult in terms of virus extraction and culti-
vation (Schutten 2006), and exhibiting result variability for different donors (Mayers
et al. 1992; Japour et al. 1993). In the late 1990s, two commercial assays were devel-
oped, Antivirogram® and Phenosense®. Both of these recombinant virus assays use a
molecular HIV clone with pol gene deficient sequences (Subsection 2.2.3), the missing
sequences added from the patient-derived HIV. After transfecting the HIV permissive
cells with this clone, the newly created viral vectors are cultured in vitro at different drug
concentrations. The main difference between these methods is that Phenosense® assay
uses vectors which, apart from RT and PR, are also deficient in the env gene, which is
replaced by luciferase reporter gene. These vectors are transfected to cells which addi-
tionally contain an env gene-expressing plasmid, ensuring that proteins coded by this
gene are incorporated into the viral particles formed in that cell. However, these parti-
cles can only perform one cycle of infecting new cells as they do not have env in their
RNA (Subsection 2.2.4), reducing the turnaround time and reproducibility of this assay
(Petropoulos et al. 2000). Another difference between the two assays is that the viral
replication in Phenosense® is quantified by luciferase activity, while in Antivirogram®
the cytopathic effect (cell killing) is measured.
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3.1.4 Blot-Based Protein Detection
Western blot is a blot-based technique for separating and identifying proteins. In this
technique gel electrophoresis is used to separate a mixture of proteins based on their
molecular weights. These gels are then transferred to a membrane, which produces visible
bands for each protein. In a typical two-step procedure, first primary antibodies specific
to the protein of interest are incubated together with the membrane. After washing
the membrane, only the antibody bound to the protein of interest remains. A secondary
antibody is then added which binds to the primary antibody, and it is this antibody that
is used for signal detection. There are different options for performing signal detection.
One of them is colorimetric detection, where a reporter enzyme bound to the secondary
antibody stains the membrane by converting a soluble dye to one in a solid state. In
the chemiluminescence detection approach, a substrate is used which luminesces when in
contact with the reporter on the secondary antibody, which is captured by CCD cameras.
In another approach called fluorescence detection, the probe is excited by light and its
emission of excitation can be detected by CCD cameras.
In a simplification of the Western blot, a so-called dot blot procedure, the sample is
applied directly on the membrane instead of using electrophoresis. This saves time by
eliminating the need to use blotting on gel procedure, but because of this removal it
provides no information about the protein size.
Descriptions of the theoretical foundations in Sections 3.2.2 and 3.2.3
follow in argument and in notation (Gapsys et al. 2015), Section 3.2.4
follows (Lindahl 2015), and Section Partial Charges follows (Woods
and Chappelle 2000; Schlick 2002).
3.2 Computational Methods
3.2.1 Protein Mutation Modelling
Point mutation modelling in proteins is a problem related to protein homology mod-
elling (Khan et al. 2016). Here, instead of aiming to computationally predict the whole
structure of an unknown protein based on a homologous protein with a similar primary
sequence and a known three-dimensional structure, the task is to predict the changes
in the known protein structure upon replacement of a single amino acid. For this pur-
pose, rotamer libraries based on analysis of known protein structures are typically used.
These libraries can be split into protein backbone-independent (Ponder and Richards
1987; Tuffery et al. 1991; Maeyer et al. 1997; Lovell et al. 2000) and backbone-dependent
(Dunbrack and Karplus 1993; Bower et al. 1997). Most of the available tools for intro-
ducing point mutations use the latter approach (Chinea et al. 1995; Schwede et al. 2003;
R. E. Smith et al. 2007; Feyfant et al. 2007), where, given backbone ψ and ϕ angles
positions, one aims to fit proper side-chain rotamers. In effect, the methods boil down
to the tasks of (i) conformational search of placing the side-chains and (ii) scoring the
created models. Historically, newer methods give more emphasis to the latter (Liang
and Grishin 2002; Feyfant et al. 2007). Overall, different side-chain prediction methods
have been suggested to yield similar results (Xiang and Honig 2001). Furthermore, if
the models created are used to perform molecular dynamics simulations, different con-
formations of the protein structure are sampled in the simulation as governed by the
underlying force field.
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3.2.2 Free Energy
Free energy in this dissertation refers to the thermodynamic free energy, or the amount
of work that a system can perform. Based on the second law of thermodynamics, a
closed system will minimise its free energy until it reaches equilibrium at the free energy
minimum. The thermodynamic free energy can be described as the Helmholtz free energy
or Gibbs free energy. While both are applicable at constant temperature conditions, the
difference between the two is that the former describes processes under constant volume
(isochoric) conditions and the latter at constant pressure (isobaric) conditions. Since in
most biochemical processes no changes of pressure occur, processes which minimize the
Gibbs free energy are the main driving force.
In statistical mechanics, the Boltzmann distribution describes the probability p to
observe a specific state x depending on its free energy:
p(x) ∝ e
− G(x)kβT , (3.1)
where kβ is Boltzmann’s constant and T is the absolute temperature.




− G(A)−G(B)kβT = e
∆G
kβT , (3.2)
where ∆G is referred to as the free energy difference.






where GA is the Gibbs free energy of phase space in volume A, G is the Gibbs free energy
of the whole phase space of the system, and β = 1
kβT
.
The free energy difference between two states GAB can also be expressed in the fol-
lowing terms:












where Q = Q(N, P, T) is referred to as the canonical partition function of the phase
space for N number of particles in pressure P.
Replacing G with F in Equations 3.3 and 3.4 results in the Helmholtz free energy
formalism, with a difference in the definition of Q = Q(N, V, T) with volume V of
the container. The partition function relates to the Helmholtz free energy via F =
− 1
β
ln Q(N, V, T) and it is defined as follows:






e−βH(p1···pN ,q1···qN)d3 p1 · · · d3 pN d3q1 · · · d3qN , (3.5)
where H(p, q) is a Hamiltonian, which describes the total energy of the system in terms
of coordinates p and momenta q, and h is the Planck’s constant.
The partition function can be rewritten for constant pressure P as follows:






e−βH(p1···pN ,q1···qN)+PVd3 p1 · · · d3 pN d3q1 · · · d3qN . (3.6)
Gibbs free energy relates to this partition function as G = − 1
β
ln Q(N, P, T).
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3.2.3 Free Energy Estimation
Free Energy Perturbation
The formalism for the Free Energy Perturbation (FEP) method for the free energy
difference estimation introduced by Zwanzig (Zwanzig 1954) can be derived from Equa-
tion 3.4:









where ⟨· · · ⟩ denotes the average of an ensemble. This value can be estimated by equi-
librium sampling the system at state A and evaluating the difference of the Hamiltonian
of states B and A of the resulting configurations.
Another way of estimating the free energy difference by sampling the end state of a






⟨ f (HA(p, q)− HB(p, q) + C)⟩B
⟨ f (HB(p, q)− HA(p, q)− C)⟩A
+ C, (3.8)
where f (x) = 1
1 + eβx









, with nA and nB
denoting the number of configurations generated in states A and B. Equation 3.8 can
be solved numerically by finding C, such that
∑
B
f (HA(p, q)− HB(p, q) + C) = ∑
A
f (HB(p, q)− HA(p, q)− C). (3.9)








So far Zwanzig’s FEP approach has been defined in terms of sampling the end state
of a system and BAR in both end states. The accuracy of these methods depends on
the phase space overlap between states A and B, since otherwise the system sampled at
A (or B) will have high energy state in terms of the Hamiltonian HB(p, q) (or HA(p, q)),
meaning that these configurations will contribute little to the exponential average in
Equations 3.7 and 3.8. A coupling parameter λ overcomes this by allowing unphysical
intermediate states (also called alchemical) Hλ = (1 − λ)HA − λHB. By using strat-
ification with λ ∈ [0..1] an alchemical pathway can be created between A and B by
ensuring there is phase space overlap between the neighbouring states. Summing up the
Zwanzig’s FEP or BAR estimates of the free energy difference between neighbouring
states results in the estimate of ∆GAB.
Thermodynamic Integration
Another method for free energy change estimation dependent on a coupling parameter λ
is called Thermodynamics Integration (TI) (Kirkwood 1935). It is conceptually different
from the approaches above in that the ∆GAB is obtained by integrating the average force
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Several different implementations based on TI can be used in simulations for estimating
the free energy change. In the case of slow growth TI, a transition along λ is performed
very slowly to keep the system close to equilibrium at all times, so that the work done
along the pathway corresponds to ∆G. In the discrete thermodynamic integration, the
path along λ is divided into discrete steps and an equilibrium simulation is performed for
evaluating ⟨δH
δλ
⟩λi at each λi. The numerical integration of the averages then corresponds
to the ∆GAB value. Similarly to FEP and BAR, a large overlap between neighbouring
ensembles along the λ coordinate is required for an accurate ∆G estimate.
Non-Equilibrium Methods
The methods for free energy estimation discussed so far depend on the system being at
equilibrium with its surroundings at all times. If it is not, friction will result in non-
equilibrium work done, which on average will tend to increase the ∆G estimate. In 1997
Jarzynski (Jarzynski 1997) derived an equation which enabled the calculation of ∆G
from work W, which is done during a non-equilibrium transition of a system:
e−β∆GAB = ⟨e−βW⟩. (3.12)
The non-equilibrium transitions are still required to be started from an equilibrium







Similarly to FEP, the convergence of this method depends on the occurrence of rare
events, during which little work is dissipated. A relation which combines the work value
distributions from both forward f and backward r transitions to obtain the Helmholtz
free energy has been derived by Crooks (Crooks 1998; Crooks 1999) (it was later shown





The previously introduced BAR estimator can also be used for non-equilibrium sim-

















giving the maximum likelihood estimator of the free energy difference.
3.2.4 Molecular Dynamics Simulations
Two computational techniques that are prevalent to produce statistical mechanics ensem-
bles are Molecular Dynamics (MD) and Monte Carlo (MC) simulations. Both approaches
rely on the systems being ergodic, meaning that the time average (for MD) or the en-
semble average (for MC) of a single molecule in a long simulation should correspond to
the instantaneous ensemble average over all molecules in an experimental measurement
of the same system. While there is disagreement on which technique is more efficient in
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producing this ensemble (Jorgensen and Tirado-Rives 1996; Yamashita et al. 2001), the
advantage of MD over MC is that it gives dynamic information about the system.
A set of parameters that underlay an MD simulation of a system of atomic particles
is referred to as Molecular Mechanics (MM) force fields. They are derived empirically
and/or from Quantum Mechanics (QM) (Guvench and MacKerell 2008). In the force
fields, typically a distinction is made between bonded interactions and non-bonded inter-
actions. The former covers stretching of covalent bonds, angle-bending, as well as torsion
potentials when rotating around the bonds. The latter is described by the attractive-
repulsive Lennard-Jones potential and Coulomb electrostatic potentials. The simulation
itself proceeds in an iterative manner, where given the initial coordinates and forces of
all atoms in the system, the coordinates are updated for the next step.
To remove possible clashes between atoms before the actual MD simulation, typically
a steepest descent algorithm is used to move atoms in the direction of decreasing en-
ergy. The MD simulation that follows performs the integration of Newton’s equations
of motion:
Fi =






MD simulations are carried out in a box of fixed dimensions, and to avoid artefacts at
the boundaries of this box so-called periodic boundary conditions are used. Essentially
this means an infinite grid of copies of the simulation box, where a molecule exiting the
box in simulation in one dimension enters it from the opposite side. For non-bonded
interactions this means that the infinite number of interactions should be summed. In
practice a cutoff is used for the Lennard-Jones potential, while the Particle-Mesh-Ewald
(PME) is used to calculate the infinite electrostatic interactions by dividing the summa-
tion into short- and long-range parts (Essmann et al. 1995).
When simulating an NPT ensemble, the temperature and pressure have to be con-
trolled. During the simulation, as the potential energy decreases, the kinetic energy,
which is related to the temperature, increases. To control this, the system is typically
coupled to a thermostat, whose function is to scale the velocities during the integration
to maintain the temperature. Similarly, the total pressure of the system is controlled
by a barostat which scales the simulation box size.
To access long time-scales of simulation, increasing the time step is desirable. This is
however limited by the highest frequency motions in the simulated system, amounting to
the fact that errors introduced from the bonds’ vibrations manifest themselves already
at 1 fs. Bond constraint algorithms such as SHAKE (Ryckaert et al. 1977) and LINCS
(Hess et al. 1997) are thus used to remove these oscillations, allowing the use of 2 fs time
steps in simulation.
The Born-Oppenheimer approximation (Born and Oppenheimer 1927), which sep-
arates the motion of atomic nuclei and electrons, has an important role in MD. Its
manifestation here is that in MD it is nuclei that are the point particles that follow the
Newtonian dynamics. Thus, the classical MD is suitable for a wide range of problems,
including modelling the conformational changes of organic and inorganic molecules and
their non-covalent interactions. For studying important electronic changes such as the
bond formation, a QM or hybrid (QM/MM) treatment is needed.
Partial Charges
An important set of parameters in the force fields that allows for modelling of electro-
static energies is that of the partial charges, which, despite being artificial, is particularly
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relevant for biomolecules. Partial charges are assigned to the atoms by optimising the
fit (χ2esp) between the classical Coulomb model for the electrostatic potential (V̂) and




(Vi − V̂i)2, (3.16)




. The bond polarity overestimation has been suggested to be an issue
for these charges, for which reason attenuating with χrestr was recommended in the






where χ2rstr = krstr ∑j(
√
q2j + b
2 − b). b determines the tightness of the hyperbola around
its minimum and krstr determines the strength of the restraint function.
Ab initio quantum mechanics is one way to acquire V, which implies a non-empirical
solution to the Schrödinger equation. In these methods, the molecular orbitals are ap-
proximated by a linear combination of atomic orbitals, which are defined for specified
basis sets, such as Gaussian functions. The coefficients that describe this linear combina-
tion are calculated by minimizing the electronic energy (known as Hartree-Fock energy)
of the molecular system for a given set of chosen orbitals.
3.2.5 Prediction of Acid Disassociation Constant
Proteins’ ionisable groups have an important function for the intra-protein, protein–
solvent, and protein–ligand interactions, which in turn play an important role in protein
folding, binding of interaction partners, and catalytic activity. Together with the ad-
vancing experimental procedures for pKa determination, a large body of computational
efforts has been invested in developing tools for calculating pKa (see (Alexov et al. 2011)
for review). In effect, the computational methods try to predict the change in the model
residue’s pKa values in solvent when this residue is moved into protein, or the ∆pKa.
One of the major directions of research for this purpose has been to numerically solve
the linearised Poisson–Boltzmann (PB) equation, which describes the electric potential
in solution normal to the charged surface (Bashford and Karplus 1990). PB models,
which sample protonations at a fixed conformation, have been combined with MM/MD
methods, which sample conformations at a fixed protonation (Machuqueiro and Baptista
2006). A much less computationally demanding alternative is implemented in empiri-
cal methods such as Propka (H. Li et al. 2005), which use simple empirically estimated
terms to evaluate the influence of hydrogen bonds, desolvation effects, and charge–charge
interactions on the residue’s ∆pKa.
4
Drug Resistance Mutations of HIV-1
Protease
This chapter describes work performed on the drug resistance mu-
tations of the HIV protease. Part of the study which concerns the
resistance mutations G48V, I50V, and L90M was done in collabo-
ration with Vytautas Gapsys, Nadezhda T. Doncheva, Rolf Kaiser,
Bert L. de Groot, and Olga V. Kalinina and published in [Bastys
et al. 2018]. I have written the manuscript for the publication and
the corresponding text and figures in this chapter have been adapted
from that publicationa. The second half of the study has been done
in collaboration with the same people and additionally with Hauke
Walter providing the experimental resistance factor measurements for
the L76V mutation. The manuscript for that study is currently in
preparation. I performed all the computational work described in this
chapter, except for the implementation of the method for calculating
the resistance factor values which was done by Vytautas Gapsys.
a Reproduced in part with permission from T. Bastys et al. [2018]. “Consis-
tent Prediction of Mutation Effect on Drug Binding in HIV-1 Protease Using
Alchemical Calculations.” Journal of Chemical Theory and Computation 14.7,
pp. 3397–3408. doi: 10.1021/acs.jctc.7b01109. Copyright 2018 American
Chemical Society.
As outlined in Section 2.2, the HIV epidemic, which started over twenty years ago, re-
mains a global health hazard. Despite the many different ART options, drug resistance
is still an issue. Current treatment protocols include PIs, nine of which are currently
marketable as FDA-approved treatments against the HIV protease (Antiretroviral Drugs
Used in the Treatment of HIV Infection n.d.). Nevertheless Resistance-Associated Muta-
tions (RAMs) can arise against all of them (The Stanford HIV Drug Resistance Database
n.d.).
In this chapter a study of the molecular mechanisms of the HIV protease RAMs is
presented. The focus of this study is the use of MD simulations to estimate the effect of
the mutation on the free binding energy of the inhibitors and to relate these resulting
observations to the experimental measurements of the same values, as well as to the Re-
sistance Factor (RF) measurements. The underlying energetic and mechanistic reasons
for the mutations’ effect on inhibitor binding are also analysed to gain understanding of
the underlying molecular reasons for the drug resistance and sensitivity phenomena.
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4.1 Introduction
Acquiring resistance against antiviral drugs by HIV-positive patients can have a num-
ber of underlying causes, including treatment adherence failure, sub-optimal treatment
regimen prescribed, disease stage at the time of treatment initiation, pharmacogenetics,
drug–drug interactions, failure to monitor viral load, or interruption of treatment due to
medication availability. Some of these and other causes are exacerbated in the countries
with resource-limited settings. Treatments which combine multiple drugs, including the
ones targeting different HIV proteins, raise the barrier for drug resistance. Some specific
mutations, which exhibit resistance-inducing, as well as sensitizing effect towards dif-
ferent drugs, give an opportunity to efficiently combine ARV drugs (Larder et al. 1995;
Ziermann et al. 2000; Wiesmann et al. 2011). Drug tolerability is one of the limiting fac-
tors in prescribing drug combinations; even treatments combining three different drugs
are expected to cause drug resistance after several years (The UK Collaborative Group
on HIV Drug Resistance 2005).
Resistance-associated mutations typically alter the affinity of inhibitor molecules to
their protein targets. The change in the free energy of binding of inhibitors to the target
protein, e.g. HIV protease, upon mutations, ∆∆G, measures the difference of binding
free energy between mutant protein and wildtype protein to inhibitor, ∆GMUT and ∆GWT
respectively. This change in free energy of binding is directly related to the change in
the inhibitor’s affinity to the mutant protease (and thus to the resistance phenotypes),
and hence accurately estimating the effect of a mutation on ∆∆G is highly desirable to
predict its relation to drug resistance. MD simulations of protein and inhibitor allow to
use different computational techniques for this purpose. Free Energy Perturbation (FEP)
was employed in the 1990s during the development phase of the first PIs for predicting
∆G for various, mostly experimental inhibitors (Ferguson et al. 1991; M. R. Reddy et al.
1991; Rao et al. 1992; Tropsha and Hermans 1992; Rao and Murcko 1994; X. Chen and
Tropsha 1995; Rao et al. 1996; Rao and Murcko 1996; M. R. Reddy and Erion 1998;
McCarrick and Kollman 1999), but also in some more recent studies (E. C. B. Johnson
et al. 2007; Y. Yu et al. 2015; S. T. Ngo et al. 2015). Thermodynamics Integration (TI)
has also been applied for the same purpose (Cai and Schiffer 2010; Deng et al. 2015).
A conceptuatly different set of techniques developed in the late 1990s for estimating
free energy of binding of small ligands and macromolecules are the so-called Molecu-
lar Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) and Molecular Mechan-
ics/Generalized Born Surface Area (MM/GBSA) methods (Srinivasan et al. 1998; Koll-
man et al. 2000). The names stem from their using molecular mechanics energy terms
describing bonded, electrostatic, and van der Waals interactions and combining them
with polar and non-polar solvation free energy terms, estimated by solving Poisson-
Boltzmann equation or by using generalized Born model and solvent accessible surface
area accordingly. Another term included in the analysis performed by these methods is
entropy, estimated from normal-mode analysis of the vibrational frequencies, multiplied
by temperature term. Unlike the alchemical methods, in these methods sampling is
performed only in the end states (the complex and possibly free ligand and receptor),
thus MM/PB(GB)SA are also referred to as end-point methods. Widely used due to
their computational efficiency, MM/PB(GB)SA have also been applied extensively for
studying the HIV protease–ligand complexes (Kalra et al. 2001; Hou and R. Yu 2007;
Kožíšek et al. 2007; Altman et al. 2008; Hou et al. 2008; Hou et al. 2009; Stoica et al.
2008; Wittayanarakul et al. 2008; Alcaro et al. 2009; J. Chen et al. 2009; Hu et al. 2010;
Shi et al. 2009; Cai and Schiffer 2010; J. Chen et al. 2010; Sadiq et al. 2010; Kar and
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Knecht 2012a; Kar and Knecht 2012b; D. Li et al. 2012; Meher and Y. Wang 2012;
Srivastava and Sastry 2012; Tzoupis et al. 2012; D. Li et al. 2014; Wright et al. 2014; R.
Duan et al. 2015). However, studies using these methods which include a comparison to
the experimental ligand binding affinities (Hou and R. Yu 2007; Kožíšek et al. 2007; Hou
et al. 2009; Stoica et al. 2008; Wittayanarakul et al. 2008; Hu et al. 2010; Cai and Schif-
fer 2010; J. Chen et al. 2010; Sadiq et al. 2010; Kar and Knecht 2012a; Kar and Knecht
2012b; Meher and Y. Wang 2012; Tzoupis et al. 2012; Wright et al. 2014; R. Duan et al.
2015) are limited in their scope, i.e. in the number of mutations/inhibitors analysed, or
often have poor correlation to the experimental estimates. It has been shown that the
performance of these methods in terms of reproducing the ∆G of a ligand binding to a
protein varies depending on the system (Kuhn et al. 2005; D. A. Pearlman 2005; Hou
et al. 2011; Genheden and Ryde 2015).
In an experimental setting, the resistance of mutant proteins towards inhibitors, such
as in the studies mentioned above, is typically measured in terms of the Inhibitor Con-
centration required to reduce enzymatic reaction activity by 50% (IC50) or the Effective
Concentration corresponding to the half-maximal response (EC50). Thus, in the HIV
research the ratio between IC50 or EC50 in mutant and the same measurement for the
wildtype protease (typically with the consensus sequence from the HXB2), also called
RF, is a useful descriptor for resistance of different mutated proteins. RF is directly
related to the free energy of inhibitor binding, ∆G, and the protein enzymatic activity,
Km (Cheng and Prusoff 1973).
Studies of inhibitor affinity to the protease based on MD simulations also give a unique
information into their structures, interactions, and changes thereof in time. Comparing
wildtype and mutant complexes can therefore provide information on the underlying
physical reasons of the effect that the mutation has on inhibitor binding. This knowl-
edge can help in designing inhibitors with minimal vulnerability towards the resistance
mutations of HIV protease, as well as potentially other viruses proteases, which are
typically present in human-infecting viruses (Kräusslich and Wimmer 1988; Tong 2002)
(for review on strategies on improving HIV and Hepathitis C Virus (HCV) protease
inhibitors against resistance see (Yilmaz et al. 2016)). While some studies analyse the
mechanistic effect of the select major RAMs on binding of different inhibitors (Hou and
R. Yu 2007; Muzammil et al. 2007; Alcaro et al. 2009; Shen et al. 2010; Mittal et al.
2013; R. Duan et al. 2015; Y. Yu et al. 2015), and other analyse the effect of differ-
ent RAMs on binding of the same inhibitor (Liu et al. 2005; Kovalevsky et al. 2006;
Kožíšek et al. 2007; Hu et al. 2010; Cai and Schiffer 2010; J. Chen et al. 2010; Kar and
Knecht 2012a; Meher and Y. Wang 2012; Ragland et al. 2014; Ragland et al. 2017), most
of the studies are focused on single mutation and inhibitor combinations, particularly
for major RAMs outside of the binding pocket, offering only a limited perspective on
molecular mechanisms of protease resistance. The mechanism of action of a mutation
on binding of different inhibitors is particularly interesting for those cases, where the
same mutation is known to cause resistance to some drugs, while making the protein
sensitive towards others. Such mutations are for example L76V, which is associated with
resistance towards APV, Indinavir (IDV), Darunavir (DRV), and Lopinavir (LPV), but
decreased resistance towards Atazanavir (ATV) and Saquinavir (SQV) (T. P. Young et
al. 2010; Wiesmann et al. 2011), or N88S, which is a RAM towards IDV and Nelfinavir
(NFV), but increases susceptibility towards APV (Ziermann et al. 2000; Resch et al.
2002; Vermeiren et al. 2007) or its prodrug FPV (Rhee et al. 2010).
In this chapter, a diverse set of HIV protease RAMs, both inside and outside the
binding pocket, is analysed. These RAMs are divided into three parts: dataset 1 for
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different mutations with experimental measurements of ∆∆G, dataset 2 for different
mutations with experimental measurements of RF, and dataset 3 for L76V mutation in
different sequence backgrounds with experimental measurements of RF. We demonstrate
using dataset 1 that alchemical free energy calculations using a non-equilibrium approach
based on MD simulations allow for an accurate estimation of the impact of mutations
on inhibitor binding for a set of different RAMs in combination with different inhibitors.
We show an overall good correlation of the estimated and empirical ∆∆G values and
emphasize the importance of the correct choice of the protonation state for the two
aspartic acid residues in the active site. We also demonstrate using datasets 2 and 3
that we can in general faithfully reproduce the effects of RAMs on IC50. It is then
analysed how the effects of the mutation propagate in the protease structure to affect
the inhibitor binding at a site that can be remote from the mutated amino acid residue.
We show coupled effects among different protease residues affecting the binding of the
inhibitors. Thus, novel and general insights into the development of HIV resistance to
drugs are provided.
4.2 Methods
4.2.1 Drug Resistance Measuring for Protease Acquired from Patient
Samples
The experimental data in dataset 3 was derived from samples of patients who underwent
multiple therapy failures with different PIs. These viral variants displayed resistance
and re-sensitising effects of the PIs LPV and SQV. Those variants were observed in the
diagnostic procedure, sequenced, and subsequently tested in a phenotypic assay. The
tests were carried out after the patient’s variant was cloned into a recombinant derivate of
the HIV NL4-3, called pNL4-3-Delta-PRT5. These variants were analysed in cell culture
experiments where they were exposed to different PIs in different concentrations to
estimate their RF values (Table 4.1). Based on these variants, the clones were specifically
modified by site-directed mutagenesis so that different variants of L76V could be tested
in different genetic backgrounds. For simplicity, from here on regardless of the residue
at position 76 of protease as present in the original clinical samples, L76 will be referred
to as wildtype residue and V76 as the mutant residue as per HXB2.
4.2.2 System Preparation
Crystal structures of protease–inhibitor complexes were obtained from the Protein Data
Bank (Berman et al. 2000) (PDB IDs 1HPV (APV), 1HXB (SQV), 1K6C (IDV), 1MUI
(LPV), 1SDT (IDV), 2BPX (IDV), 2O4K (ATV), 2O4P (TPV), 2O4S (LPV), 3EKV
(APV), 3EL1 (ATV), 3NU3 (APV) and 3PWR (SQV)). Modeller (Sali and Blundell
1993) version 9.12 was used to introduce mutations targeted in this study as well as
the background mutations. Mutation I50V was introduced in structures 1SDT, 2O4K,
2O4P, 2O4S, and 3NU3, as well as mutations G48V, L90M, and G48V/L90M in structure
1HXB. For other RAMs analysed in this study, additional background mutations were
required, described in the following, where first the background mutations are listed
followed by the structure name and the RAM analysed (plus the genotype identifier in
cases where L76V was studied) in the parenthesis:
• Q7K in 1HPV (I50V)
• Q7K in 2BPX (I50V)
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Genotype ATV SQV IDV LPV
FB15 L76 63 74 – –V76 0.9, 2.3, 4.5 3.6, 4.6, 5.8 – –
GH9 L76 90 18.6 – –V76 1.2, 2.4, 3.2, 3.6, 1.9 1.2, 1.3, 1.5 – –
RU1 V76 2.7 – – 157L76 9, 10, 8.4 – – 27, 47, 46
iZ2 V76 4.1 – 59 71L76 12, 7.8, 30 – 7.9, 10, 2.2 11, 12, 5.5
Table 4.1: Protease RF values for dataset 3, with multiple measurements for the same
protein separated by comma. For each genotype the first row represents the
wildtype position as in the original sample and the second row represents the
mutation introduced at position 76.
• K7Q, R14K, R57G, T82V, and V84I in 1K6C (N88S)
• K7Q, R14K, K41R, and V77I in 3EKV (N88S)
• L10F and S37N in 1MUI (I84V)
• L10F and S37N in 1HPV (I84V)
• S37N and A71V in 1HPV (M46I)
• L10F and S37N in 2BPX (I84V)
• S37N and A71V in 2BPX (M46I)
• K7Q, I13V, G16E, K20I, I33F, M36L, S37N, I62V, I63H, A67C, A71V, G73S,
I84V, L90M, and 95C in 3PWR (V76L in the genotype FB15)
• K7Q, I13V, G16E, K20I, I33F, M36L, K41R, I62V, P63H, V64I, A71V, G73S,
I84V, and L90M in 3EL1 (L76V in the genotype FB15)
• K7Q, L10V, I13V, G16E, K20R, I33L, E35D, M36I, S37N, M46I, I54V, Q58E,
I62V, I63H, I64V, A67C, V82F, I84V, and A95C in 3PWR (V76L in the genotype
GH9)
• K7Q, L10V, I13V, R14K, G16E, K20R, E35D, M36I, K41R, M46I, I54V, Q58E,
I62V, P63H, V82F, I84V in 3EL1 (L76V in the genotype GH9)
• K7Q, L10V, I13V, R14K, K20M, E35D, M36I, M46I, I54V, Q58E, P63L, V64I,
H69K, V82M, and L89I in 3EL1 (L76V in the genotype RU1)
• L10I, I13V, K20M, E35D, M36I, S37N, R41K, M46I, I54V, Q58E, H69K, V82M,
and L89I in 1MUI (L76V in the genotype RU1)
• K7Q, L10I, I13V, R14K, L24I, L33F, K46L, I62V, A71V, T82A, V84I, and Q92K
in 1K6C (L76V in the genotype iZ2)
• L10I, I13V, L24I, L33F, S37N, M46L, I62V, L63P, A71V, and V82A in 1MUI
(L76V in the genotype iZ2)
• K7Q, L10I, I13V, R14K, L24I, L33F, K41R, M46L, I62V, V64I, A71V, V82A, and
Q92K in 3EL1 (L76V in the genotype iZ2)
In two cases where the RAM I50V was analysed, we have investigated viral strains con-
taining additional mutations L33I, L63I, C67A, and C95A, for which we used structures
1SDT and 3NU3. Denoted I50V* in this study, these mutations are introduced to pro-
tect the protease against autocatalysis as well as cysteine thiol oxidation; however this
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practice is not universally applied (Muzammil et al. 2007). All of the aforementioned
mutations were introduced in both protease monomers in consistency with the data from
the experimental studies of HIV protease and HIV infection in vivo (Josefsson et al. 2011;
Josefsson et al. 2013).
To validate our approach of choosing the active site protonation state, the following
structures resolved by X-ray/neutron crystallography were considered: 2ZYE (with a
not used in ART inhibitor KNI-272), 5E5J (DRV), 5E5K (DRV), and 5T8H (APV).
Hydrogen atoms were assigned to aspartic acid, glutamic acid, and histidine residues as
they were resolved in the corresponding structures, with the exception of 5E5J, where
D30 was assigned a deprotonated state as the deuterium atom in that structure had 50%
occupancy on D30 and K45 residues (Gerlits et al. 2016), and 5E5K, where the E34 was
assigned a protonated state as this state was inferred in the original study (Gerlits et al.
2016).
In the following, preparation for simulation of all the structures mentioned above is
described in both holo and apo states. Exception to that are the wildtype and mutant
apo structures for which multiple complexes had the same protein sequence (with mu-
tation indicated in the parenthesis): 1HPV (I50V), 1SDT (I50V), 2O4P (I50V), 2O4S
(I50V), 2BPX (I50V, M46I, and I84V), 1MUI (I84V), and 1HXB (I84V), whose simu-
lation was not required (see Section 4.2.4). The Gromacs simulation software package
was used to set up (versions 4.6.2 and 4.6.5), carry out, and analyse the MD simulations
(versions 5.0.2 and 5.1.2) (Hess et al. 2008; Abraham et al. 2015). All crystallographic
water and ion molecules were retained. The pKa of residues was predicted using Propka
(Søndergaard et al. 2011) and the protease was assigned a monoprotonated state on
either D25/D25′, where the prime refers to the second subunit of the protein. Excep-
tion to that were structures 3NU3 and 1SDT, where previously suggested protonation
was used (R. Duan et al. 2015), and 1HXB, where similar pKa values (6.42 and 6.47)
were predicted for both active site residues and protonation of D25 was chosen. The
mutant reference protein protonation state was considered to be the same as that of the
wildtype protein. The summary of protonated aspartic acids for all the complexes is
reported in Tables B.1, B.4, and B.5. The Amber99SB*-ILDN force field was used for
the protease parametrisation. Chemaxon Calculator (Chemaxon Calculator 5.3.8 n.d.)
was used to determine ligand protonation. Ligands ATV, LPV, APV were assigned
neutral charge, IDV and SQV were assigned a +1 charge, and TPV was assigned a
−2 charge. Gaussian09 (Frisch et al. 2010) was used to optimize ligand geometry and
calculate the electrostatic potential at the HF/6-31G* level of theory. Partial charges
were assigned by performing RESP fit (Bayly et al. 1993). Bonded parameters and atom
types were obtained from the Generalized Amber Force Field (GAFF) (J. Wang et al.
2004). ACPYPE (Silva and Vranken 2012) was used for file conversion into the Gromacs
format. The complex was solvated in TIP3P water molecules with 1.4 nm buffer in each
dimension with 0.15 mol/L concentration of Cl and Na ions (Joung and Cheatham 2008)
to neutralize the system.
4.2.3 Equilibrium MD Simulations
Each system was subjected to energy minimization using the steepest descent algorithm.
A maximum of 5000 steps was performed until a maximum force of 1000.0 kJ mol−1 nm−1
was achieved. Ten replica 200 ns simulations for each complex were performed at 300 K
with a time constant of 0.1 ps using the velocity-rescaling thermostat (Bussi et al. 2007),
at a constant pressure of 1 atm with a time constant of 4 ps using the Parrinello–Rahman
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barostat (Parinello and Rahman 1981). The electrostatic interactions were calculated at
every step with the PME method (Essmann et al. 1995), and the short-range repulsive
and attractive dispersion interactions were simultaneously described by a Lennard-Jones
potential with a cutoff of 1.2 nm. All bonds were constrained using the LINCS algorithm
(Hess et al. 1997) and a time step of 2 fs was adopted. Simulated annealing in length
of 1 ns was performed to avoid a too close contact between atoms before equilibrium
simulation for 2BPX (50V variant) in both protonation states, 5E5J in D25′ protonation
state, 1MUI (76V for genotype iZ2) in D25′ protonated state, 1MUI (76L for genotype
iZ2) in D25 protonated state, 2BPX (46V and 84I variants) in D25 protonated state,
3EKV (88S variant) in D25 protonated state, and 3EL1 (76L and 76V for genotype
iZ2) in D25′ protonated state. For all of the analyses that followed, the first 20 ns of
the simulations were considered to be a part of the system equilibration process and
thus discarded, with the exception of free energy calculations, where first 10 ns were
discarded.
4.2.4 Free Energy Calculations
The protocol for free energy calculations was adjusted from the non-equilibrium simula-
tion approach used in assessing changes in protein thermal stabilities and protein–protein
interactions upon amino acid mutation (Gapsys et al. 2016). For calculating the free en-
ergy change upon mutation of apo structures, ∆G1, estimates for the following structures
were used in multiple ∆∆G estimates where the same mutation (indicated in parenthesis)
in the same background sequence (as indicated in Section 4.2.2) was analysed: 2O4K
(I50V), 3NU3 (I50V), and 1HPV (M46I and I84V). From each of the equilibrium simula-
tions described in the previous section, trajectory frames were extracted equidistantly in
time every 10 ns. For every snapshot the hybrid structures and topologies were generated
using the pmx framework (Gapsys et al. 2014) for all of the residues to be mutated. Sub-
sequently, short 20 ps simulations were performed to equilibrate the velocities. Finally,
alchemical transitions were carried out in 50 ps. Alchemical transitions were extended
to a total of 400 ps in complexes 1HPV (46I, 46M, 84I, and 84V variants) in D25 proto-
nated state and 1MUI (84I and 84V variants) in D25 protonated state when estimating
∆∆Gcalc, as well as 1K6C (88N and 88S variants) in D25 protonated state and 3EKV
(88N and 88S variants) in D25 protonated state when estimating ∆∆GprotWT and ∆∆G
prot
MUT
used in the dataset 2, because of high variance of the ∆∆G estimates from those tran-
sitions. During these transitions mutations in both of the monomers were introduced
simultaneously, resulting in four mutations for the double mutant G48V/L90M and two
mutations for the rest of the complexes. The simulation parameters for the 20 ps equili-
bration and alchemical transitions were identical to those used in the 200 ns equilibrium
simulations. During the transitions, non-bonded interactions were soft-cored (Gapsys
et al. 2012). The CFT (Crooks 1999) was used to relate the obtained work distributions
to the free energy values by employing the maximum likelihood estimator (Shirts et al.
2003). The error estimates were obtained by the bootstrap approach.
4.2.5 Combining Free Energy Estimates from Alternative Protonation
States
To include the contributions of the alternative protonation states in the binding free en-
ergy change upon mutation, we need to add the free energies of those states for wildtype
and mutant proteins. Assume that in our calculation of ∆∆Gcalc in both cases D25 was
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protonated and D25′ was not and refer to it as state A. Then we want to estimate for
both proteins G(B), i.e. the free energy of protein where D25′ is protonated, which per
Equations 3.4 and 3.7 corresponds to:
G(B) = − 1
β
ln p(B). (4.1)
Assuming there are only two possible protonation states for each protein, using p(A)+





From Equations 4.1 and 4.2 we arrive at the final estimate of binding free energy
change upon mutation, ∆∆Gtotal:










4.2.6 Assessing the Resistance Factor Ratio from the Inhibitor Binding Free
Energy Change
Cheng-Prusoff equation (Cheng and Prusoff 1973) relates inhibitor’s IC50 and binding
affinity Ki (Equation 2.9), which in turn can be estimated from the inhibitor binding free
energy ∆G (Equation 2.10). Thus, given two RF values for two proteases with sequences





























kβT C , (4.4)
where ICWT50 refers to the reference wildtype protein. We are interested in obtaining a
distribution of the RFR values after calculating the double free energy differences ∆∆G:
p(RFR|∆∆G, C) ∝ p(∆∆G, C|RFR)p(RFR). (4.5)
When there are multiple RFR measurements and ∆∆G calculations available, C can
be expressed as a function of the available values C = Ci(∆∆Gi,RFiR), i = 1, . . . , n. This
gives the final posterior distribution:
p(RFR|∆∆G, ∆∆Gi,RFiR) ∝ p(∆∆G, ∆∆Gi,RFiR|RFR)p(RFR), (4.6)
where Ci = RFiRe
−∆∆Gi
kβT . The ∆∆G values are sampled from a Gaussian distribution with
the mean and standard deviation corresponding to the calculated double free energy
difference and estimated error, respectively.
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4.2.7 Partial Least-Squares Regression
Partial-Least Squares (PLS) regression was performed using the functional mode analysis
tool (Krivobokova et al. 2012). The following sets of input atoms (excluding hydrogen
atoms) were used for the model: backbone, ligand, protein, and side chain. Constants 0
and 1 have been used as response variables for trajectories corresponding to mutant and
wildtype protein simulations, respectively.
Cross validation for each mutation and inhibitor combination was done as follows:
all trajectories for wildtype and mutant complexes were concatenated, superimposed to
minimize the variance over the ensemble (Gapsys and Groot 2013), and divided into five
equal parts. In each iteration, a model was trained on four parts of labelled input in equal
parts from wildtype and mutant simulations, after which it was used to make predictions
for the last part. The Pearson correlation between the actual signal and prediction was
used to measure the prediction quality. The number of components in the final model
has been selected using the so-called “elbow method”, where the model complexity is
increased by boosting the number of components until adding further components only
marginally improves the quality of prediction (Tibshirani et al. 2001).
4.2.8 Mutual Information
Mutual Information (MI) I between pairs of backbone ϕ and ψ, as well as side chain
χ dihedral angles of residues was estimated from their individual and joint entropies
using the MutInf (McClendon et al. 2009) method. Twenty-four bins were used to
get the discrete distributions of the dihedral angles. Dihedrals from 10 simulations
for each case were kept separate for the later evaluation of Iind, or the excess mutual
information, for pairs of torsion angles from independent simulations. Monte Carlo
sampling with adaptive partitioning of all torsion angle pairs was used to obtain a
background distribution of I, and only those I entries which had a p-value of at most
0.01 according to this distribution were retained. False positives were removed based on
P(I < E[Iind]) criteria, namely that the true mutual information is lower than expected
for independent torsion angles, Iind. Iind is then subtracted from the actual I so that
incomplete sampling resulting from memory effects in the simulations can be corrected
for. The mutual information for any two residues, Ires, is then estimated as the sum of
the mutual information between pairs of those residues’ torsion angles. For more details
on the methods described we refer to the original paper (McClendon et al. 2009).
Bootstrap sets were created for each set, by randomly selecting with replacement n
frames from a simulation of length n. This was done for each of the 10 simulation runs
while preserving the same order across the different dihedral angles and simulation runs,
repeating this procedure 10 times. For each resulting bootstrap set, I was estimated.
The mean and standard deviation of Ires from the 10 bootstrap sets, µIres and sdIres
respectively, were then calculated. When comparing the actual residue pairs, IresWT and
IresMUT , for wildtype and mutant simulations for some complex, only those cases were








from the bootstrapped sets. As a final filter, residues whose differences in Equation 4.7
were smaller than or equal to 0.3 kT were not considered for further analysis.















∆∆GprotMUT = ∆G2 − ∆G1
Figure 4.1: Thermodynamic cycles for estimation of ∆∆G of protease-inhibitor complex
upon mutation. The first cycle estimates the mutation effect on ligand bind-
ing, the second cycle estimates the effect of switching the proton between
D25/D25′ for wildype protein, and the third cycle switches correspondingly
for the mutant protein. Only the binding pocket is shown in the figures;
the wildtype protein is shown in grey, the mutant is shown in blue, and the
inhibitor is shown in orange. In the second and third cycles the inhibitor is
set to semi-transparent for reasons of clarity, and the proton in question for
D25/D25′ is shown as a black sphere.
4.3 Results
4.3.1 Estimation of the Change in Binding Free Energy with Explicit
Probing of the Protonation State of the Active Site
As in all aspartyl proteases, the catalytic site of the HIV protease comprises two aspartic
acid residues, of which only one is protonated in its active form (Hyland et al. 1991). In
the HIV protease these residues are D25 and D25′ from the two subunits of the dimer
that lie next to each other in the binding pocket (Figure 2.5). The three-dimensional
structures of the HIV protease considered in this study have been obtained by X-ray
crystallography, which typically does not provide information on the positions of hy-
drogen atoms. Hence it is unknown which of the two catalytic aspartate residues is
protonated in each case. The apo form of the enzyme is symmetric, thus switching the
protonation state of the two aspartic acid residues results in an identical dimer. On the
other hand, protease inhibitors considered here are not symmetric molecules, and upon
their binding to the protease, the resulting complex is no longer symmetric. Previous
studies have suggested that the protonation state of the protease depends on the in-
hibitor bound (Baldwin et al. 1995; X. Chen and Tropsha 1995; Y. X. Wang et al. 1996;
Tawa et al. 1998; Adachi et al. 2009; Kar and Knecht 2012a). For a complex with an
experimental inhibitor including a diol group, a diprotonated HIV protease at its active
site has been suggested (Yamazaki et al. 1994), but such a state seems to be rather an
exception (McGee Jr et al. 2014).
In this study both monoprotonated active site states are considered in order to find
the complex with the lowest free energy. In each case studied, MD simulations were
conducted in both alternative protonation states (DH25/D25′ and D25/DH25′) for the
wildtype and the mutant. The reference protonation state was identified with Propka
(Søndergaard et al. 2011), with the exception of complexes analysed for I50V*, where
the previously suggested protonation was used (R. Duan et al. 2015) (Table B.1). We
then estimated the difference of the binding free energy in the wildtype and the mutant
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ATV I50V 2.7a 0.02 ± 0.19 −1.80 ± 0.16 −1.16 ± 0.2 0.34 ± 0.32
LPV I50V 2.6a 1.39 ± 0.15 −0.81 ± 0.26 −0.1 ± 0.48 1.74 ± 0.57
TPV I50V 2.1a 0.9 ± 0.18 1.04 ± 0.3 −0.56 ± 0.21 0.1 ± 0.41
APV I50V 2.5a 1.16 ± 0.17 −1.24 ± 0.17 −0.81 ± 0.27 1.38 ± 0.37
IDV I50V 1.9a 0.82 ± 0.12 0.91 ± 0.29 0.73 ± 0.27 0.73 ± 0.41
APV I50V* 2.03b 2.11 ± 0.15 1.47 ± 0.35 −0.33 ± 0.45 1.21 ± 0.58
IDV I50V* 2.33c 0 ± 0.1 −2.49 ± 0.45 −1.82 ± 0.76 0.32 ± 0.89
SQV G48V 2.78d 3 ± 0.58 0.67 ± 0.15 0 ± 0.24 2.66 ± 0.65
SQV L90M 1.60d −0.09 ± 0.24 —”— 1.03 ± 0.18 0.09 ± 0.33
SQV G48V/L90M 4.03d 5.32 ± 0.74 —”— 2.1 ± 0.21 6.03 ± 0.79
Table 4.2: Experimental and estimated ∆∆G values for dataset 1 in kcal/mol. a ∆∆Gexp
taken from (Muzammil et al. 2007). bc Ki values taken from (Shen et al.
2010) and (Liu et al. 2005) respectively and ∆Gexp calculated using ∆Gexp =
−RT ln Ki. d Ki values taken from (Ermolieff et al. 1997) and (Maschera et al.
1996), ∆Gexp1 and ∆Gexp2 calculated using ∆Gexpj = −RTj ln Kij and ∆Gexp
at 300 K temperature then calculated by linear interpolation between ∆Gexp1
and ∆Gexp2 .
complexes between the two alternative protonation states, ∆∆GprotWT and ∆∆G
prot
MUT (Table
4.2, Figure 4.1). Large differences in the binding free energy between the two protonation
state alternatives can be observed in several cases, e.g. −2.49 kcal/mol for IDV bound to
the wildtype protease. Interestingly, the reference protonation state corresponds to the
lowest free energy complex only in 44% of the cases (8 out of 18), indicating that Propka
cannot be used as a reliable means for predicting protonation for the HIV protease. For
some inhibitor/mutant combinations, the lowest free energy complex for the mutant has
the opposite protonation state compared to the wildtype, i.e. the mutation affects the
protonation probabilities upon inhibitor binding. Concomitantly, the interactions in
the vicinity of the active site differ between the wildtype and the mutant enzymes, as
demonstrated by the interaction energy analysis in Section 4.3.3. Analysis of an exper-
imental structure of HIV protease in complex with APV resolved with X-ray/neutron
crystallography (Weber et al. 2013), where the protein has the same sequence as the
wildtype in our analysis of the I50V* mutation supports our assertion. In this structure,
the hydrogen atoms on the aspartic dyad were resolved and the protonated aspartic acid
residue matched the lowest free energy prediction for both complexes with APV from
our study.
To further test the accuracy of our method in predicting the energetically favourable
active site protonation state, we searched the PDB for structures of HIV protease with
experimentally resolved hydrogen atoms. This resulted in a dataset of four additional
protease complexes, including one with APV, two complexes with DRV resolved under
different pH conditions, and one with an experimental inhibitor KNI-272. In all cases, the
free energy change ∆∆Gprot of switching the proton from active site aspartic acid, which
was resolved experimentally, to the active site aspartic acid on the opposite monomer was
estimated to be energetically unfavourable (Table B.2). This included the two complexes
with DRV, where the only manifestation of differences in experimental pH values in our
simulations was in terms of different protonation states of several residues, including the
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AUE = 1.4 kcal/mol
Figure 4.2: Calculated total estimate and experimental measurement of binding free
energy change upon mutation for dataset 1.
active site. Here we correctly predicted the opposite active site protonation states of
these complexes.
Taking into account the alternative protonation states of the active site, we measured
the total difference of the binding free energy between the wildtype and the mutant
complex, ∆∆Gtotal, as defined in Equation 4.3. Considering the alternative protonation
states results in a correlation between ∆∆Gexp and ∆∆Gtotal of 0.89 (average unsigned
error 1.4 kcal/mol) (Figure 4.2).
It must be noted that for many of the complexes studied, there is a compensation in the
changes of the binding free energy caused by switching the active site protonation state
between the complexes. That is, if the simulation of a wildtype protein in the reference
state was in an energetically unfavourable protonation state, the corresponding mutant
protein also had a tendency to be in an energetically unfavourable protonation state
which means they compensated each other to some degree in the overall estimate of ∆∆G
(Figure 4.3a). This results in a high degree of correlation between ∆∆Gtotal and ∆∆Gcalc
(Figure 4.3b). Thus we evaluated how accurate can one expect to be in estimating
∆∆G if one were to choose randomly which of the active site residues is protonated in
both wildtype and mutant protein. For that purpose all unique combinations of ∆∆G
estimates for the set of all ten complexes were probed, where ∆∆G was a result of any




MUT. For each of these
sets its correlation r with ∆∆Gexp was calculated, which resulted in 410 data points
(Figure 4.3c). Correlation between ∆∆Gexp and ∆∆Gtotal (r = 0.89) was higher than
with the mean ∆∆G from all possible combinations (r = 0.81), with ∆∆Gcalc (r = 0.79)
or ∆∆Gpropka (r = 0.81) (the latter corresponded to the evaluation of the most likely
protonation state as predicted by Propka separately for wildtype and mutant protease
complexes). This confirms the benefit of combining the simulations of HIV protease
in both active site protonation states for obtaining the best accuracy when estimating
the effect of mutation on ligand binding free energy. Thus we used this approach in all
further calculations of this value and from here on ∆∆G refers to the complete estimate
including simulations in both protonation states.
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(c) Correlations of ∆∆G and ∆∆Gexp
Figure 4.3: Effect of protease D25/D25′ protonation choice on ∆∆G for dataset 1
through comparison of (a) free energy of switching the protonation between
active site residues in wildtype and mutant proteins, (b) calculated total esti-
mate and calculated estimate of free energy binding change upon mutation
where a single, reference protonation state was used, and (c) distribution
of correlations between the experimentally measured binding free energy
change upon mutation and calculated one, where all possible combinations
of protonation states of wildtype and mutant protein have been considered.
p corresponds to the probability to observe correlation r higher or equal
than the one in question when choosing a random protonation state.
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4.3.2 Estimation of Resistance Factor Ratio from the Inhibitor Binding Free
Energy Change
Mutation Background IDV SQV LPV FPV
M46I wildtype V3, N37, V71 0.6, 1.0, 1.2 – – 0.3, 0.6, 0.7mutant 4.4 – – 2.2
I84V wildtype V3, F10, N37 1.5 1.3 1.6 1.8mutant 2.1, 3.2 2.7, 3.7 6.2, 7.7 4.6, 8.4
N88S wildtype V3, N37, P63, G57/I77* 1.1 – – 1.0mutant 2.6 – – 0.1
Table 4.3: RF values from the HIVdb, further referred to as dataset 2. First column
indicates the mutation analysed, while the second column indicates back-
ground mutations in both wildtype and mutant sequences compared to the
reference HIV sequence HXB2. * indicates that the G57 background muta-
tion was found in the sequences where RF for IDV was measured and I77 in
the sequences where RF for FPV was measured. Nota bene: M46I wildtype
and mutant measurements are reported in different studies, but performed
using the same susceptibility test method.
Given the successful application of the method in reproducing the experimental esti-
mates of the mutations’ effect on inhibitor binding affinity ∆∆G, we went a step further
to analyse whether the effect of RAMs on IC50 could be predicted. More specifically, we
aimed at evaluating whether the experimentally measured RFR between two protease
complexes differing in one mutation can be reproduced using the inhibitor binding free
energy change upon mutation in the protein. For this purpose we selected dataset 2
comprising of sixteen complexes from the HIVdb database (The Stanford HIV Drug Re-
sistance Database n.d.) for which resistance factors for inhibitors APV, IDV, LPV, and
SQV were measured experimentally as reported in the literature (Tables 4.3 and B.3).
These complexes could be paired amongst each other such that the RF has been mea-
sured for the same inhibitor and the same protease strain with and without the mutation,
namely: IDV and APV with mutation M46I; APV, IDV, LPV, and SQV with mutation
I84V; APV and IDV with mutation N88S. Moreover, for all of these mutations there was
a correspondence of wildtype and mutant protein background sequences across the differ-
ent inhibitors, with the exception of N88S, where complexes with APV had a background
mutation L77I and complexes with IDV had a R57G background mutation present. Both
R57G and L77I mutations are found next to each other on two parallel beta-sheets on
the side of the protease. Although they are close to the resistance-associated positions
76 and 54, respectively, unlike for those residues, side chains of residues 77 and 57 are
pointing away from the protease binding pocket. Nevertheless the mutation R57G has
been suggested to be a protease-inactivating mutation (Ott et al. 2003). L77I on the
other hand, has been reported to be a compensatory mutation for I84V restoring protein
stability (M. W. Chang and Torbett 2011). M46I, I84V, and N88S are all considered to
be major RAMs against the corresponding inhibitors as reported in the HIVdb, with the
exception of N88S, where sensitivity towards APV/FPV was reported (Ziermann et al.
2000; Resch et al. 2002; Vermeiren et al. 2007; Rhee et al. 2010). Accordingly, for all
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Inhibitor Mutation ∆∆G RFR
APV M46I −0.35 ± 0.4 3.67–7.33*
IDV M46I −0.34 ± 0.72 3.14–7.33
APV I84V 2.06 ± 0.47 2.56–4.67*
IDV I84V 1.13 ± 0.57 1.4–2.13
LPV I84V 1.25 ± 0.39 3.88–4.81
SQV I84V 0.56 ± 0.41 2.08–2.85
APV N88S −0.97 ± 0.7 0.1*
IDV N88S 1.41 ± 0.95 2.27
Table 4.4: Change of the binding free energy ∆∆G of inhibitors upon mutation for
dataset 2, values in kcal/mol, and ± shows bootstrap error estimate. Last
column indicates the RFR value range from previously reported experimental
RF measurements, where * stands for measurements for FPV, the prodrug
of APV.
of these pairs, protease with a RAM had a higher RF than the wildtype, while N88S
reduced resistance towards APV in dataset 2.
We performed MD simulations of all the complexes and calculated the effect of mu-
tations on the free energy of inhibitor binding. Overall resulting ∆∆G calculations indi-
cated a good agreement between the effect of mutations on the free energy of inhibitor
binding and their effect on RF, including the opposite effects of N88S towards IDV and
APV (Table 4.4; for protonation switch estimates see Table B.4). An exception to that
is M46I, where the mutation had a modest effect on ∆G which was within the error
estimate.
A possibility of effect of mutations on the catalytic activity of the enzyme, Km, pre-
cludes direct comparison of the ∆∆G estimates of mutation effects on the free energy
of inhibitor binding and the RFR corresponding to that mutation. In previous stud-
ies on resistance mutations of another enzyme of HIV, reverse transcriptase, ∆∆G was
considered to approximate changes in IC50 (Rizzo et al. 2000; D.-P. Wang et al. 2001;
Udier-Blagović et al. 2003). This is however a strong assumption, at least in case of the
HIV protease, in which mutations were reported to affect its catalytic activity (X. Chen
and Tropsha 1995; Pazhanisamy et al. 1996; Schock et al. 1996; Nijhuis et al. 1999).
Similarly to the case of the reverse transcriptase studies, we had available only the ex-
perimentally measured effects of mutation on IC50 for the same enzyme but different
inhibitors. To account for the potential problems mentioned, we developed a Bayesian
method which combines estimates of the effect of mutation on Km from different com-
plexes to calculate RFR (see Section 4.2.6). We then compared the estimated RFR values
to the their experimental measurements (Figure 4.4). The increase of resistance towards
inhibitors (RFR> 1) was correctly predicted for all mutations, as was the sensitizing
effect of N88S towards APV (RFR< 1), and the experimental RFR values were within
the corresponding calculated distributions based on the ∆∆G estimates (Figure B.1).
The third and final dataset which we analysed, dataset 3, included RF measurements of
HIV protease acquired from clinical isolates in the presence and absence of hydrophobic
core RAM L76V (Table 4.1). The RF measurements confirmed the resistance-inducing
effect of this mutation against IDV and LPV, as well as the sensitizing effect towards ATV
and SQV reported previously (T. P. Young et al. 2010; Wiesmann et al. 2011). Since,
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Figure 4.4: Predicted and experimental RF measurements for dataset 2. Each symbol
corresponds to a unique sequence background and each colour corresponds
to an inhibitor. Nota bene: in case of APV, RFexpR measurements are for its
prodrug FPV.
similarly to the case of dataset 2, the effect of the mutation on inhibitor binding was
measured in different background sequence contexts and towards different inhibitors,
the same approach for estimating RFR from ∆∆G could be applied for this dataset,
too. Because the sequences of the protease complexes analysed had a large number
of background mutations accumulated (compared to the reference sequence HXB2), it
was difficult to find complexes in PDB with similar sequences. Thus in the protein
modelling stage between 11 and 19 mutations had to be introduced to create protein
models with sequences corresponding to those for which RFR was measured (see Section
4.2.2). Including the target mutation L76V as well meant that up to 20% of protease
residues had to be modelled in silico.
First we estimated the effect of the mutation L76V on inhibitor binding in terms of
the change of the binding free energy ∆∆G (Table 4.5). The increase of the binding
free energy, corresponding to the decrease in inhibitor affinity, was predicted for all
complexes where mutations were observed to increase the protease RF. The decrease of
RF, on the other hand, did not always correspond to a negative value of ∆∆G: L76V
was predicted to increase the affinity of inhibitor binding for inhibitors ATV and SQV
only for the genotype GH9, but not for the genotype FB15, nor for inhibitor ATV in
the context of the genotypes RU1 or iZ2. Of these genotypes, FB15 and iZ2 lack the
background mutation M46I (the former being wildtype at that position and the latter
having mutation M46L), which has been suggested to co-occur with L76V to compensate
for its compromising effect on the replication capacity of HIV (Nijhuis et al. 2009; Louis
et al. 2011).
We then used the ∆∆G estimates to calculate RFR (Figure 4.5). For most of the
complexes we correctly predicted whether the mutation made the protein more resistant
or more sensitive towards the inhibitor. This included the prediction of sensitizing effect
of mutation in the genotype FB15 for both ATV and SQV for which the inhibitor affinity
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Inhibitor Mutation ∆∆G RFR
ATV FB15 0.78 ± 0.64 0.01–0.07
SQV FB15 0.69 ± 0.62 0.04–0.08
ATV GH9 −0.29 ± 0.49 0.01–0.04
SQV GH9 −0.58 ± 0.47 0.06–0.08
ATV RU1 0.74 ± 0.73 0.27–0.32
LPV RU1 1.52 ± 0.6 3–5
ATV iZ2 1.11 ± 0.65 0.14–0.53
IDV iZ2 1.76 ± 0.66 5.9–26.82
LPV iZ2 0.99 ± 0.88 5.91–12.9
Table 4.5: Change of the binding free energy ∆∆G of inhibitors upon mutation L76V in
dataset 3, values in kcal/mol, and ± shows bootstrap error estimate. Last
column indicates the RFR value range from experimental RF measurements.




















Figure 4.5: Predicted and experimental RF measurements for dataset 3. Each symbol
corresponds to a unique sequence background and each colour corresponds
to an inhibitor.
increased based on the ∆∆G estimates. Sensitization towards ATV was on the other hand
not observed for genotypes RU1 and iZ2. The experimental RFR values were however
within the corresponding calculated distributions based on the ∆∆G estimates (Figure
B.2).
4.3.3 Molecular Mechanisms of Resistance
Energetic Contributions of Individual Residues
To elucidate the energetic interactions of individual residues with the inhibitor, for each
of the residues contributions of Lennard-Jones and short range electrostatic terms were
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Figure 4.6: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes. Residues, for which the difference
(EMUT − EWT) between the wildtype and mutant complexes is higher than
the propagated error (SE) and its absolute value is higher than 0.1 kcal/mol,
are represented as a coloured circle, where the colour represents the relative
interaction energy and the size of the circle relates inversely to the standard
error of the estimate.
calculated and their comparison was made between the wildtype and the mutant com-
plexes for RAMs G48V, I50V, and L90M, referred to as dataset 1 in this dissertation
(Figure 4.6). In all cases, only the complexes with the protonation states corresponding
to the lowest free energy were considered.
For the inhibitors ATV, LPV, TPV, and APV, the mutation I50V leads to an increase
in the interaction energy between the inhibitor and the protein (Figures 4.6 and B.3),
which may account for the observed resistance in this phenotype. The experimental
measurements from ITC for ATV, LPV, and APV reported an enthalpic penalty ∆∆H,
i.e. losses in the binding enthalpy of inhibitor upon mutation, which also includes the
direct protein–inhibitor interactions, caused by the I50V mutation (Muzammil et al.
2007). This was not the case for TPV, where a reduction in ∆∆H was reported for
the same mutation (Muzammil et al. 2007). Mutation A71V, which tends to appear
together with I50V (Mittal et al. 2013), is known to compensate for the loss of viral
fitness due to primary RAM (Nijhuis et al. 1999). An ITC study of I50V+A71V double
mutant (Mittal et al. 2013) suggested an increase in affinity toward ATV as a result of an
increase in entropy which compensated the increase in enthalpy. The same compensatory
effect in that study was observed for APV, but with the overall result of a binding
penalty for the inhibitor. In the present study the mutation I50V* decreased the direct
interaction energy between the protein and APV. This was mostly the result of a stronger
interaction with the active site residues due to a difference in protonation state preference
between the wildtype and mutant. To test whether the addition of mutation A71V
results in a different thermodynamic profile, additional simulations of a 50V+71V mutant
4.3 Results 49
with the ATV and APV inhibitors were performed. The resulting ∆∆G, 0.91 and 1.27
kcal/mol respectively, was close to the original estimates for a single mutation I50V for
these inhibitors and it exhibited comparable direct protein–inhibitor interaction profiles
(Figure B.3). Thus, the compensating effect of the double mutation in our simulation
could not be reproduced. Similarly to APV, I50V and I50V* showed differing protein
interaction profiles with IDV, with the former exhibiting stronger direct interactions and
the latter having a small penalising effect on the interactions after mutation (Figures 4.6
and B.3). In combination with SQV, mutations G48V, L90M, and G48V/L90M had an
unfavourable effect on the direct protein–inhibitor interaction energy, albeit to a smaller
extent for the single-site mutations (Figure 4.6).
Direct protein–inhibitor interaction profiles were also calculated for the L76V muta-
tion in the context of different background sequences (Figure B.4). We observed that
the mutation has an unfavourable effect on direct protein–inhibitor interactions for all
complexes with LPV (albeit to a small extent for the genotype iZ2) and with SQV; a
favourable effect was observed for complexes with ATV (albeit to a small extent for
the genotype RU1) and IDV. It should be noted that for mutations which change the
preference of the protonation state of the active site residues D25/D25′ of the protease,
namely FB15 and GH9 with SQV, as well as iZ2 with IDV (Table B.5), the largest ener-
getic contributions overwhelming all others come precisely from the active site residues.
Interestingly, measurable differences were observed for interactions of the residue at po-
sition 76 with the inhibitor for complexes of genotype FB15 with LPV and ATV and
genotype iZ2 with IDV. But given that the side chain of residue 76 has minimal exposure
to the binding pocket, those differences are small. Overall these effects of a mutation on
the direct protein–inhibitor interactions are only partially in line with the effect of the
mutation on binding free energy of the inhibitor.
Changes in Protease Structure and Residues Interactions
For all complexes with mutations G48V, L90M, and particularly I50V analysed (dataset
1), if the substitution had any notable effect on the direct interaction energy between pro-
tease and inhibitor, such effect extended beyond the mutated residue itself. The largest
contributions were observed for residues in the flap region, i.e. near the mutation site.
Other proximal affected residues were in the 80s loop, as well as around the active site
(Figures 4.6 and B.3). A similar effect was observed for mutation L76V (dataset 3) (Fig-
ure B.4). Given such a wide distribution of mutation effects, we decided to investigate
for dataset 1 whether this is related to structural changes in the protease or to a different
pose of the inhibitor. Functional mode analysis based on PLS regression (Krivobokova
et al. 2012), a supervised machine learning technique, allows to study the correlation of
Cartesian input from MD trajectories to a desired functional property. In the present
study we investigated whether the major collective motions discriminate the wildtype
and mutant complexes: using Cartesian coordinates as an input, we attempted to predict
whether a trajectory was generated by a wildtype or a mutant protein. This technique
was applied with different input features: coordinates of heavy atoms of the backbone,
inhibitor, protein, and side-chain, to create statistical models. Of these, for mutations
of dataset 1 models with protein backbone input proved to be the most predictive and
models with inhibitor input proved to be the least predictive in the cross-validation on
average (Figure B.5). Models trained on protein backbone atoms proved to be capable
of making a satisfactory distinction for all complexes except IDV in the context of I50V*
and complexes with SQV in the context of the G48V or L90M mutations. Mapping the
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Figure 4.7: Interpolation between the extremes of the PLS models for the corresponding
complexes. Blue-to-magenta bands correspond to the interpolation along the
mode which relates the true label of simulation, wildtype or mutant, to the
underlying differences in protein motions.
regions of the backbone contributing the most to the discriminative power of these PLS
models confirmed the flap as the region that is the most important for distinguishing the
trajectories of wildtype and mutant complexes (Figures 4.7 and B.6). The 80s loop is
also prone to assume different conformations between wildtype and mutant complexes,
as well as the loop with the active site residue, particularly so for cases in which the
energetically favourable protonation state differs between wildtype and mutant proteins
(Figures 4.7a and 4.7b).
The analysed mutations seem to have an effect on direct protein–inhibitor interaction
as well as on protein backbone rearrangements outside of the immediate mutation site.
Certainly, this must be the case for RAMs which are not in direct contact with the
inhibitor, such as the mutation L90M. However no consistent effect of this mutation was
observed in terms of changes in the protein backbone and just a minor effect on the
protein–inhibitor interaction. To gain insight into other non-local effects of the muta-
tions, differences in the correlated motion of all pairs of residues between the wildtype
and the mutant protease-inhibitor complexes were inspected. Since these correlations
are not necessarily linear, it was chosen to evaluate the pairwise mutual information
based on the distributions of dihedral angles from molecular dynamics simulations (Mc-
Clendon et al. 2009), a measure that depends both on individual Shannon entropies of
the residues and their joint entropy.
First we inspected in which protein regions correlations are affected most by inhibitor
binding. For this purpose residues’ mutual information between apo and holo wildtype
proteins were compared (Figure B.7). The flexible flap region for all of the complexes
is affected to the largest extent. Correlations in the active site loop of the protease, as
well as the 80s loop also, seem to be affected in many cases, particularly so upon binding
of TPV and SQV. These results are expected, since the flap and 80s loop regions are
suggested to be involved in inhibitor binding (Spinelli et al. 1991; Perryman et al. 2004;
Perryman et al. 2006; Y. Yu et al. 2015), while the active site D25/D25′ typically makes
hydrogen bonds with the inhibitor upon its binding, thus likely affecting its interactions
with other residues in the protein.
Next, we estimated the mutual information network for holo protein complexes with
mutations and compared it to the wildtype holo protein complexes in order to evaluate
how the mutation affects residues’ correlated motions in the protein (Figure 4.8). We
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(a) L90M SQV (b) G48V SQV
(c) G48V/L90M SQV (d) I50V ATV
(e) I50V LPV (f) I50V TPV
(g) I50V APV (h) I50V IDV
(i) I50V* APV (j) I50V* IDV
Figure 4.8: Mutual information mapped onto the protease structure. Cylinders con-
necting residues represent differences in mutual information between those
residues in mutant and wildtype simulations, with the width of the cylin-
der proportional to the difference and red indicating higher correlation in
mutant and blue indicating higher correlation in the wildtype protein. This
corresponds to the degree to which residue pairs exhibit differences in the
correlation of their motions.
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measured what is the overlap between such pairs with those whose correlations were
affected by inhibitor binding in the wildtype complexes. To evaluate the overlap between
these sets, the Jaccard index was used, which is the ratio of the size of the intersection
of the two sets and the size of their union. A Jaccard index close to 1 indicates that
there is a high overlap between the sets of such pairs, whereas an index close to 0 would
indicate that different residue pairs show correlated movements in the processes related
to binding and propagation of mutation effects. An average Jaccard index value of 0.28
indicates that overall similar residue pairs are involved in these processes, but some
differences exist (Table B.6). In contrast, when we choose random pairs to form sets
of the same respective sizes as in the original data, an average Jaccard index value is
0.003. More generally, upon closer inspection it was observed that while the identity of
the residues in these pairs may differ, they are located in the same protein regions: the
flaps, the 80s loop, and the active site loop (Figures 4.8 and B.7).
Finally we analysed in detail the effect of mutations on the protein mutual information
network. For the mutation L90M, the correlated motion of the mutation site with the
active site residues D25/D25′ is changed. The active site residues directly interact with
the inhibitor (Figure 4.8a), suggesting a path by which the mutation L90M, which is
not located in the inhibitor binding pocket, affects its binding. The changed interaction
pattern between L90M and the active site residues has been observed previously in
crystal structures (Hong et al. 2000) and MD simulations (Ode et al. 2006). It has
also been noticed that the side chain I84/I84′, which is typically in direct contact with
D25/D25′, is oriented differently upon the mutation L90M (Ode et al. 2006), suggesting
changes in the binding pocket of the protease. Indeed, in the present analysis, I84
demonstrates significant differences in the correlated motion with multiple residues in
the binding pocket, as reflected by high values of the mutual information, for all three
G48V, G48V/L90M, and L90M mutants in complex with SQV. These differences are
possibly the result of different χ angle distributions of I84 between wildtype and mutant
complexes (Figure B.8). Strong differences in mutual information involving the flap
region of the complexes with SQV were also observed (Figures 4.8a-4.8c) and to a smaller
extent in complexes with other inhibitors (Figures 4.8d-4.8j). Suspecting that such large
differences are related to large structural rearrangements in the protease upon mutation,
we performed Principal Component Analysis (PCA) on the backbone of the complexes
involving SQV. The motion along the first principal component, which accounts for most
of the structural variance, indeed showed the largest shifts in the 80s loop and the flap
region (Figure B.9).
Next we focused on the structural changes of the protease in the genotypes FB15, GH9,
RU1, and iZ2 in dataset 3 where the mutation L76V was introduced, for which purpose
first we analysed the hydrogen bond network of the protein. It could be consistently seen
across all of the different genotypes, that the mutation L76V increases the probability
of observing hydrogen bond between residues D30 and K45 (Figure 4.9 and Table 4.6).
These residues are located in the active site loop and flap respectively, both regions
for which the direct interaction energies with inhibitor are affected by the mutation,
including residues D30 and to a smaller degree K45 (Figure B.4). Seeking whether this
was as a result of side chain rearrangement, we performed the PLS regression analysis
on the heavy atoms of the protein (excluding mutation site). In analysing PLS models,
we could see that the mutation L76V caused the tendency of the side chains of residues
D30, K45, and Q/E58 to shift towards the binding pocket (Figure B.10). This shift is
likely the result of fine rearrangement of residues in the region as a consequence of a
larger side chain of leucine being replaced by a smaller valine. Specifically, the changes
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Figure 4.9: Hydrogen bonds between the protease residues D30 and K45 are shown with
green dashed lines.
Drug Genotype D30–K45 D30
′–K45′
0000L76 V76 000L76 000V76
ATV FB15 0.068 ± 0.003 0.52 ± 0.04 0.07 ± 0.002 0.58 ± 0.02
SQV FB15 0.12 ± 0.01 0.59 ± 0.02 0.11 ± 0.005 0.62 ± 0.004
ATV GH9 0.07 ± 0.01 0.49 ± 0.12 0.06 ± 0.002 0.66 ± 0.12
SQV GH9 0.07 ± 0.004 0.46 ± 0.04 0.01 ± 4 × 10−5 0.19 ± 0.04
ATV RU1 0.05 ± 0.001 0.43 ± 0.05 0.04 ± 1 × 10−4 0.61 ± 0.09
LPV RU1 0.01 ± 3 × 10−5 0.16 ± 0.03 0.16 ± 0.006 0.56 ± 0.12
ATV iZ2 0.16 ± 0.007 0.57 ± 0.07 0.08 ± 0.002 0.52 ± 0.04
IDV iZ2 0.1 ± 0.01 0.39 ± 0.03 0.06 ± 0.002 0.51 ± 0.07
LPV iZ2 0.04 ± 5 × 10−4 0.19 ± 0.02 0.24 ± 0.01 0.63 ± 0.02
Table 4.6: Average hydrogen bonds number between residues D30 and K45 for protease
wildtype and mutant complexes in dataset 3. ± indicates standard error of
bond frequency across independent simulations.
of the D30/D30′ interactions with the inhibitor are in general in line with changes of
RFR, namely, negative (or favourable) interaction energy corresponding to RFR < 1 and
positive (or unfavourable) interaction energy corresponding to RFR > 1. Exceptions to
that are the protease of the iZ2 genotype when in complex with IDV, where a favourable
effect on D30/D30′ direct interaction energy with inhibitor is observed (Figure B.4h),
and the same enzyme in complex with LPV, where no notable effect on this interaction
can be suggested from the simulations (Figure B.4i).
Given the observation that the mutation L76V affects the hydrogen bonding network
of the protease, question arose on whether another mutation distant from the active
site analysed in dataset 2, N88S, potentially also affects the protein’s hydrogen bond
network. In the analysis of N88S in complex with both APV and IDV the following
effect was observed: S88 formed a hydrogen bond with D30 more frequently than N88,
and N88 formed a hydrogen bond more frequently with T31 and T74 compared to S88
(Table B.7).
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4.4 Discussion
In this study, we demonstrate the applicability of alchemical free energy calculations
for an accurate estimation of the change of binding free energy, ∆∆G, for different mu-
tations in the HIV protease and different inhibitors. Taking into account alternative
protonation states of the two aspartates in the protease active site improves in correla-
tion with experimental ∆∆G values, compared to choosing one state based on empirical
pKa calculations with Propka (Søndergaard et al. 2011). A recent study of protonation
of aspartic proteases, including HIV-1 protease, also suggested inaccuracy of prediction
of protonation state using Propka (Huang et al. 2017). Although the importance of
choosing the correct protonation state has been noted in multiple studies (Baldwin et
al. 1995; X. Chen and Tropsha 1995; Y. X. Wang et al. 1996; Tawa et al. 1998; Wit-
tayanarakul et al. 2008; Adachi et al. 2009; Kar and Knecht 2012a), predictions based
on empirical pKa estimates, as well as setting the protonation state based on a previous
suggestion for protein–inhibitor complex, regardless of the specific sequence context, still
remain a standard practice. The current study suggests that an explicit probing of both
protonation states is needed to reproduce the correct ensemble. It was observed that
choosing an alternative protonation state can contribute more than 2 kcal/mol to the
change in free energy of the system. It was also shown that a point mutation can change
the preferred protonation state of the protease, contrary to the often held assumption
(Tawa et al. 1998).
For two of the complexes described here, the effect of the I50V* mutation on the
binding free energy of APV and IDV has recently been addressed by Duan et al. (R.
Duan et al. 2015) using the MM/PBSA approach. In their study, the authors could
not reproduce the experimental values when sampling from 20 ns long MD simulations
using the AMBER03 force field (Y. Duan et al. 2003) (Table B.8). In the present study,
correct trends in free energy changes for these cases were obtained, and a hypothesis for
the mechanism of resistance was provided. To compare our results for ∆∆G calculation
from dataset 1 with the results of Duan et al., snapshots from the first 20 ns of the
trajectories for all complexes were used, totalling to 20 snapshots for each forward and
backward transitions for ∆G calculations. This resulted in an overall correlation of −0.11
between ∆∆G and ∆∆Gexp. Hence insufficient sampling might have been one of the issues
contributing to the inaccuracies observed by Duan et al.
An unfavourable effect of mutation on inhibitor binding in dataset 1 has been correctly
predicted for all of the cases analysed. Of these, predictions of ∆∆G were less accurate
for complexes involving ATV and TPV for the mutation I50V, as well as to a lesser extent
for IDV for the mutation I50V and for SQV in combination with the mutation L90M,
where the complex destabilization of mutation was underestimated. The mutation I50V
is however not considered to be a RAM against either ATV, TPV, or IDV inhibitors.
Change of binding free energy ∆∆G of inhibitor upon mutations M46I, I84V, N88S,
and L76V was also computationally estimated in this study and, in absence of experi-
mental ∆∆G values, it was compared to the effect of these mutations on experimentally
measured RFs. In most cases a positive value of ∆∆G corresponded to an increase of RF
and a negative ∆∆G to decrease of RF. Exceptions to this trend are the complexes of
the protease with the mutation M46I and inhibitors APV and IDV, where a negligible
favourable effect on ∆G was predicted despite RFR > 1 for both cases. While M46I has
been associated with resistance towards different PIs, it typically appears in combination
with other RAMs and it has been suggested to have a compensatory function for the
protease’s catalytic activity (Ho et al. 1994; Pazhanisamy et al. 1996; Schock et al. 1996;
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Drug and mutation ATV LPV TPV APV IDV APV IDV SQV SQV SQV
combination I50V I50V I50V I50V I50V I50V* I50V* G48V G48V/L90M L90M
p-value 0.12 0.05 0.02 2 × 10−3 0.2 1 × 10−3 0.07 0.06 0.05 3 × 10−5
Table 4.7: p-values for Fisher’s exact test for over-representation in holo protein of RAM
sites amongst residues showing different correlations with other residues upon
mutation or differences in direct interaction energies with inhibitor (absolute
value larger than 0.1 kcal/mol).
Nijhuis et al. 2009; Louis et al. 2011; Henderson et al. 2012). Despite this inconsistency,
our computational predictions of RFR were all in line with the experimental estimates.
Similarly, for dataset 3, there was also disagreement between ∆∆G and RFR for the
mutation L76V in complexes with ATV and SQV (in FB15 genotype) and ATV (iZ2
genotype). Interestingly, both genotypes FB15 and iZ2 lack the background mutation
M46I, which co-occurs with L76V to compensate the latter’s diminishing effect on the
replication capacity of HIV (Nijhuis et al. 2009; Louis et al. 2011). However for this
mutation most of our computational estimates of RFR were in line with experimental
measurements too. This suggests that in the absence of the compensatory mutation
M46I, the dominant effect of the mutation L76V might be in terms of decreasing the
protease catalytic activity Km.
In the present study we show that the mutation I50V directly affects the interaction
energy between protein and inhibitor, and the resulting impact on the enthalpy can be
both unfavourable (APV, ATV, LPV, and TPV) and favourable (IDV).
Studying the structural changes in the protease, for the mutation I50V and even
to a greater degree for the mutations G48V, L90M, as well as the combination of the
latter two, we show that they perturb the correlated motions in the protein, both in the
mutation site and beyond: this seems to be caused to a large extent by the movement
of the protease flap region as well as the 80s loop. These regions, together with the
loop proximal to the active site, harbour other sites in which mutations are associated
with resistance toward PIs. In fact, major RAM sites are over-represented amongst
residues whose interactions or dynamics is changed in MD simulations upon mutation,
particularly in cases when the modelled mutation is a major RAM itself (Table 4.7).
This hints at a possible relationship between different protease residues, mutations of
which are associated with viral resistance toward inhibitors, and suggests their collective
involvement in the process of inhibitor binding.
The mutation L76V on the other hand seems to affect the hydrogen bond between
D30 and K45 residues, as their side-chains, as well as the side chain of the Q/E58
residue rearrange upon mutation. This has an effect on the direct interaction energies
of D30 with the inhibitor, which is in general in line with the effect of this mutation on
RF. These observations on energetic and structural consequences of this mutation agree
with its previously reported effects on the ligand binding affinity for the inhibitor DRV
through both changes in protein–inhibitor interactions and changes in the inter-residue
distances in the binding pocket (Ragland et al. 2014). Another study suggested highly
significant correlation between mutations of D30 and K45 (Margerison et al. 2008),
indicating the importance of interaction between these two oppositely charged residues.
Co-occurance of mutations L76V and Q58E has also been reported (Champenois et al.
2011) and both mutations were found in the patient samples RU1 in dataset 3.
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Recently, a study was reported that analysed experimentally resolved wildtype and
L76V mutant structures of the HIV protease with inhibitors DRV, LPV, TPV, as well as
two experimental compounds, GRL-0519 and GRL-5010 (Wong-Sam et al. 2018). The
study reported that mutation does not change the backbone structure of the protease,
however residue 76 loses contacts with D30 and T74, and, for structures with LPV,
a slight shift of K45 towards the binding pocket as a result of the mutation can also
be observed. Overall similar interactions were reported between wildtype and mutant
proteins with different inhibitors, with the exception of GRL-5010, which interacted with
D30′ in an altered way. These results thus partially support the observations made in
our study on the effects of the L76V mutation.
Substitution at another site of the protease distant from the binding pocket, N88S,
has been suggested to create a hydrogen bond with residue D30, which in turn affects the
interaction between D30 and the inhibitor NFV (Ode et al. 2007). Another mutation at
this site that occurs in patients treated with NFV, N88D, has been reported to co-occur
with mutation D30N, coinciding with losing interactions with residues T31 and T74
mediated by water molecules (Mahalingam et al. 2002). In the present study changes in
direct hydrogen bonds upon N88S have been consistently observed between this site and
D30, T31, and T74. Interestingly, mutation of N88, similarly to that of D30, has also
been reported to be highly significantly correlated with substitution of K45 (Margerison
et al. 2008). This points to the importance of an interaction pathway between RAM site
88 and sites 30 and 45 in a common undertone with the effect of L76V mutation on site
30 and 45 interaction.
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Linear Binding Motifs Conferring Specificity
of Protein–Protein Interactions in the
MAPK-Related Pathways
In this chapter work on protein–protein interactions based on the lin-
ear motifs is presented. In the first part of this chapter, interaction
of the docking D-motifs in the MAPKs is described. It was done
in collaboration with András Zeke, Anita Alexa, Ágnes Garai, Bálint
Mészáros, Klára Kirsch, Zsuzsanna Dosztányi, Olga V. Kalinina, and
Attila Reményi and published in [Zeke et al. 2015]. The manuscript
was written by András Zeke and Attila Reményi. Corresponding text
and figures in Sections 5.1, 5.2, 5.3.1, 5.3.2, and 5.4 have been par-
tially adapted from that publication. I, together with Bálint Mészáros
and Olga V. Kalinina, performed the in silico analysis in this study.
My main responsibility was to collect the candidate D-motifs from
the human proteome and to build the predictive models for the D-
motif interactome. Also presented in this chapter is the work on the
clustering of phosphorylation sites. It was done in collaboration with
András Zeke, Olga V. Kalinina, and Attila Reményi. I was respon-
sible for the in silico part of this study, with the exception of tracing
the conservation of the phosphorylation sites in vertebrates, which
was implemented together with Olga V. Kalinina.
As outlined in Section 2.3, MAPK is a family of serine/threonine kinases well preserved
in the eukaryotes, which plays a role in many important signalling pathways in the
cell. Disruption of these pathways is associated with many of the major diseases affect-
ing human health, such as cancer, neurological diseases including Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis (Kim and Choi 2015), as well as
cardiovascular diseases among others (Muslin 2008). MAPK pathways have also been
suggested to play a role in HIV replication and development of AIDS (Schrager et al.
2002; Toschi et al. 2006; Barraud et al. 2008; Medders and Kaul 2011). Crucial to
the interaction between MAPKs and theirs targets, and thus for the specificity of the
MAPK-related pathways, is the presence of a so-called D-motif in the interaction part-
ner, a specific sequence motif in a protein disordered region, which binds to the surface
of MAPK.
In this chapter, a study of MAPK interactome based on D-motif identification as well
as on clustering of phosphorylation sites is presented. Section 5.1 briefly recapitulates
the specifics of MAPK signalling that employ D-motifs. As background information of
the study [Zeke et al. 2015], this section also introduces the idea of dividing D-motifs
to separate classes based on their structural binding modes as well as results of dot-blot
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experiments testing different D-motifs’ binding to MAPK. The main focus of Section
5.3.1 is presenting the different sequence-based computational predictive methods for
identifying MAPK interaction partners from different classes of D-motifs. One of the
methods, Position-Specific Score Matrix (PSSM), is then used to score the D-motifs
from the candidate MAPK interaction partners, whereas their biological classification is
discussed in Sections 5.3.2 and 5.4. In an additional study, an approach to find distinct
clusters of phosphorylation sites targeted by proline-directed serine/threonine kinases is
described in Section 5.3.3.
5.1 Introduction
Protein–protein interactions influence all aspects of cellular life and the most direct
mechanism through which proteins can influence each other is by physical contact. This
brings them into proximity so that they can exert control on each other’s activity or to
create opportunities for post-translational modification.
Protein–protein associations often involve so-called linear binding motifs which are
short protein segments (5–20 amino acid long) lacking autonomous tertiary structure.
These functional sites reside in the intrinsically disordered protein regions and adopt a
stable conformation only upon binding. Currently, it can only be guessed how abundant
linear motif-based interactions are; nevertheless, it was recently estimated that there are
approximately 100 000 linear binding motifs targeting dedicated protein surfaces in the
human proteome (Tompa et al. 2014).
As an example relevant to cellular signalling, MAPKs are prototypical enzymes that
depend on short segments from partner proteins and on their dedicated protein–protein
interaction hot spots. They mainly recognize their substrates, or target proteins, not
with the catalytic site but with auxiliary docking surfaces on their kinase domains
(Tanoue et al. 2000; Biondi and Nebreda 2003). As discussed in Section Target Recogni-
tion, the most important of these docking sites consists of a hydrophobic docking groove
and the negatively charged CD groove regions (C.-I. Chang et al. 2002) (Figure 2.7).
Together, they can bind the so-called D-motifs of the target proteins.
D-motifs are short linear motifs ranging from 7 to 18 amino acids in length and are
typically found in the intrinsically disordered segments potentially far away from the
target phosphorylation sites (Garai et al. 2012). Such docking elements are not only
restricted to the substrates: they are also found in MAP2Ks, in MAPK phosphatases
(MKPs), and in a variety of scaffold proteins. ERKs (ERK1 and ERK2), JNKs (JNK1,
JNK2, and JNK3), and the p38s (p38α-δ) control diverse physiological processes, and
they phosphorylate most of their substrates at serine-proline or threonine-proline ([ST]P)
sequence motifs. This is a very promiscuous consensus to be the only element recognised
by the catalytic site, and thus it is insufficient for selective target recognition, hence ad-
ditional linear binding motifs provide specificity of binding (G. L. Johnson and Lapadat
2002; Bardwell 2006). Therefore, the MAPK D-motif protein–protein interaction system
is an ideal test bed for linear binding motif discovery.
Several previous attempts were aimed at predicting MAPK-binding proteins from full
proteomes by using a generic consensus of D-motifs as it had been established almost
two decades ago (Sharrocks et al. 2000). This consensus was derived from an observation
that D-motifs almost always include at least a single positively charged residue (termed
the θ position: arginine or lysine) and a series of alternating hydrophobic residues (ϕ
positions: frequently leucine), connected by a linker of a variable length (Dinkel et al.
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2013). But despite the use of extensive multiple alignments and sophisticated algorithms,
predictions had only low success rates and the large-scale assessment of predicted hits
was not performed (Whisenant et al. 2010; Garai et al. 2012; Gordon et al. 2013).
In terms of experimental MAPK network discovery, ERK2 has been the most widely
explored. For example, several different methods were utilized to identify ERK2 sub-
strates by large-scale phosphoproteomics (Old et al. 2009; Pan et al. 2009; Kosako et
al. 2009; Carlson et al. 2011; Courcelles et al. 2014). Unfortunately, pairwise overlaps
between the lists of substrates are low across studies (e.g. ≈10%), with not a single over-
lap between five different studies that aimed to find ERK2-phosphorylated substrates
(Courcelles et al. 2014), suggesting a great dependence on the experimental conditions
used. It was noted that D-motif-like sequences are enriched in experimentally detected
ERK2 substrates (Carlson et al. 2011), yet the detection or verification of direct phys-
ical association were not performed. In addition, studies that used a high-throughput
approach to identify the partners of JNK1 (W.-K. Chen et al. 2014) or p38α (Bandy-
opadhyay et al. 2010) based on direct physical interaction resulted in low number of
hits. Thus, it is likely that a protein–protein interaction-based MAPK network discov-
ery could greatly benefit from a target-tailored approach, which takes into account —
and possibly capitalizes on — specific biochemical and biophysical knowledge already
available on known MAPK-partner protein interactions.
In recent years, the number of experimentally determined MAPK-partner protein
complex structures increased considerably (Garai et al. 2012). This development made
it possible to amend the definition of the underlying sequence motifs, and it became
clear that D-motifs encompass multiple classes of similarly built, but structurally distinct
linear motifs (similarly to the SH3 or PDZ-binding sequences) (Lim et al. 1994; Tonikian
et al. 2008). In the current study, it is shown that by building a strategy that can handle
this conformational diversity in binding, and using structural compatibility with specific
interaction surface topography as an additional criterion for prediction, the identification
of novel D-motifs can be dramatically improved. This analysis in combination with
tailored experimental techniques for the validation of low-affinity (1-20 µM) protein–
protein interactions produced unique, molecular-level insights into the physiological roles
of MAPK-based protein networks.
Our analysis of MAPK–D-peptide complex structures revealed distinct D-motif bind-
ing modes in the MAPK-docking groove (Figure 5.1). The hydrophobic docking groove
binds three hydrophobic amino acids in a row, while admitting two different spacing
schemes. θ to ϕ linker length determines the MAPK specificity of a given motif. These
two features can combine freely with each other, resulting in the four basic arrangements
(Figure 5.1a). For example, D-motifs from the JNK-binding scaffold protein JIP1 and
from the JNK-regulated transcription factor NFAT4 bind to the same docking surface
differently (Heo et al. 2004; Garai et al. 2012; Laughlin et al. 2012). Similarly, ERK- and
p38-binding D-motifs may also be structurally distinct. Nonetheless, D-motifs could be
described with a common loosely defined consensus: θ1−2x0−5ϕLx1−2ϕAxϕB. However,
the rules are much stricter for sequences that are compatible with a given MAPK-docking
surface in a given binding mode. Because the CD groove region of ERK and p38 is wider
compared to that of JNK, the N-termini of motifs binding to the two former kinases have
larger conformational freedom (Figure 5.1b) (Garai et al. 2012). These can be classified
as MEF2A- and DCC-type motifs named after the proteins in which they were first
identified. Some motifs with longer intervening regions also exist (HePTP) (Zhou et
al. 2006). The typical helical conformation at the N-terminus of HePTP-type docking
motif is also characteristic to some MAPK interactors from yeast (Ste7) and peptides
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(a) Different binding modes of D-motifs.
(b) Distinct binding conformations at the
CD groove, ranging from fully linear
(e.g. MEF2A, green) to highly alpha-
helical (e.g. HePTP, magenta).
(c) Structural heterogeneity of D-motifs. The combinations of the three variable features yield
structurally well-defined, distinct classes of D-motifs. JNK kinases only admit two major
types of motifs, the NFAT4 class (1-spacing, short linker) and the JIP1 class (2-spacing, short
linker). Known ERK1/ERK2 and p38 binder peptides may belong to the greater MEF2A
class (1-spacing, longer linker, linear end), the greater HePTP class (1-spacing, longer linker,
helical end), or the greater DCC class (2-spacing, longer linker, linear end). Subtypes and
other variants within a given greater class based on structures of MAPK-docking motif
complexes are also featured wherever applicable. Consensus motif of each subtype is shown
below the corresponding three-dimensional structures representing the bound complexes.
Figure 5.1: Structural classification of MAPK-docking motifs. Dashed lines indicate N-
terminal peptide regions that are usually not visible in the crystal structures.
with such motifs are known to bind human ERK2 with high affinity (Fernandes et al.
2007). Therefore, we also set up a hypothetical subclass of Ste7-type motifs, hitherto
unknown in humans (Figure 5.1c). Interestingly, D-motifs and their binding modes may
be conserved from yeast to human as the docking surface is ancient and well conserved
across all eukaryotes (Reményi et al. 2005; Grewal et al. 2006).
70 known, as well as newly discovered, constructs were tested in a dot-blot assay for
phosphorylation enhancement (see Section 5.2), and a total of 52 of these constructs were
found to interact with at least one of the three MAPKs (ERK2, JNK1, or p38α). This
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included novel interactors based on the JIP1, NFAT4, MEF2A, MKK6, DCC, and Ste7
models. Classes JIP1, NFAT4, as well as merged MEF2A and MKK6 classes (further
referred to as greater MEF2A) were considered to have enough members to use them
to construct in silico prediction models for other interactors in these classes and were
analysed in this study.
Another part of this study is on the role of the phosphorylation in human cells sig-
nalling networks. As described in Section 2.3.1, phosphorylation can have a wide range
of diverse effects on the protein, including affecting protein–protein interactions through
their presence on the binding interfaces of the proteins. Also, if multiple phosphoryla-
tion sites are found on a protein, they tend to be clustered in close proximity, thus such
clusters are potentially particularly indicative of having direct role in affecting protein–
protein binding. The goal was thus to analyse pairs of known [ST]P phosphorylation
sites in human proteins in order to see whether there are distinct groups within them
which would be potentially indicative of common downstream binding partners that
bind selectively to the phosphorylation sites in those groups.
5.2 Methods
5.2.1 Experimental Screening of D-motifs
A dot-blot assay based on substrate phosphorylation enhancement on a solid-phase sup-
port was used to test the binding of D-motifs to MAPKs. An artificial substrate was
constructed containing the D-motifs as well as the Thr71 phosphorylation site from acti-
vating transcription factor 2 (AFT2), which is a well-known MAPK target site (Living-
stone et al. 1995). After applying activated MAPKs on the assay and later washing the
assay, it was developed using western blot techniques using an anti-phospho-T71 AFT2
antibody. Phosphorylation signal was then read either by luminescence or fluorescence.
5.2.2 Selecting Ortholog Sequences and Weights Assignment
To increase the sequence space coverage in the computational prediction models of D-
motifs, more than just (known or novel) human MAPK-docking motifs were included.
A method was devised to use evolutionarily weighted sequences for each independently
evolved (or sufficiently unique) motif and to collect all known vertebrate orthologs.
For this purpose, alignments were built from vertebrate proteins obtained by BLAST
(Altschul et al. 1990) searches. Based on the refined consensus, motifs were classified
as either potentially functional or non-functional. The motifs deemed potentially func-
tional were realigned (with no gaps allowed) to the original sequence. If multiple paralog
instances were present, they were considered within the single ortholog group. Weights
were assigned to all ortholog groups using the Gerstein-Sonnhammer-Chothia scheme
(Gerstein et al. 1994) based on pairwise sequence identity. This scheme assigns lower
weight to sequences with higher identity and distant sequences receive higher weights.
The purpose of these weights is that groups of closely related sequences can make a
final contribution comparable to a contribution of a single distant sequence, account-
ing for over-representation of certain too close strains in the dataset. Finally, weights
of peptides in each ortholog group are divided by the total number of peptides in the
group.
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Position-Specific Scoring Matrix
A Position-Specific Score Matrix (PSSM) was built for each of the JIP1, NFAT4, greater
MEF2A, and greater DCC classes using formerly known and newly found, validated
human motif instances as well as all their identifiable vertebrate orthologs, including 10
residue long flanking positions from the corresponding protein. In a PSSM, each row
represents one of 20 possible residues, and each column represents a position in a motif.
Thus, the score for residue X at position i is defined in the following way:
Xi =
∑s(ws I(si = X)) + pXb
∑s ws + p
, (5.1)
where s is a peptide sequence, ws is the weight of that sequence based on the species from
which it stems, I is the indicator function, which evaluates as 1 when its argument is
true and 0 otherwise, p is the pseudo-count defined as the square root of total number of
training peptides from the class and is used to account for potential other residues that
are not observed at position i, and Xb is the overall background frequency of that residue
(based on UniProtKB/Swiss-Prot (The UniProt Consortium 2016) Release 2013.05). For
computational efficiency and to account for background frequencies of residues, log-odds
scores of Xi were used in the following form:






The score of a peptide s is then calculated as the sum of the Xi ′ scores of individual
positions i. If a peptide is missing any of the flanking positions, the average score at
that position of the whole dataset which is being scored is used instead.
PSSMs can be visualized by so-called sequence logos. In the sequence logos the height
of residue X at position i is directly proportional to its PSSM value Xi (with p = 0)
and the information content of that position Ri, which in turn depends on uncertainty
at that position Hi:
Ri = log2(20)− Hi,
Hi = ∑ Xi log2(Xi).
(5.3)
One Class Support Vector Machine
Support Vector Machine (SVM) models using string kernels were constructed using the
R package kernlab (Karatzoglou et al. 2004) with the shogun (Sonnenburg 2017)
package for computing the string kernels.During the training phase, for each string
kernel with degrees k ∈ {1, 2, 3, 4}, the number of support vectors was varied with
the parameter ν ∈ {0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.99}. SVM models using
the Radial Basis Function (RBF) kernel were constructed using the R package e1071
(Meyer et al. 2018). The physical-chemical encoding (Venkatarajan and Braun 2001)
with five parameters per residue was used for this kernel to numerically encode pep-
tides. Kernel spread was controlled with the γ parameter set to γ = 1d f , with d being
the data dimension, which equals the length of the peptide in its numerical encod-
ing, and f ∈ {0.05, 0.1, 0.2, 0.5, 1, 1.5, 2, 5, 10, 20} (with fixed ν = 0.2) or alternatively
ν ∈ {0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.99} (with fixed γ = 1d ). During the test-
ing phase, new data points were classified as belonging or not to the one class on which
the model was trained on, depending on which side of the hyperplane they fall.
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Hidden Markov Model
A Hidden Markov Model (HMM) method trained with the Viterbi algorithm, called D-
finder, was used for D-motifs scoring (Whisenant et al. 2010). The training parameters of
the learning rate (0.01) and the number of epochs in training (300) were left unmodified
from the original implementation. In the original version of the algorithm, the sequence
scanning using a basic hydrophobic site motif defined as ϕxϕ, where ϕ ∈ {V, I, L, M}
and x /∈ {V, I, L, M}, was used to down-score sequences that did not contain such motifs.
This part of the algorithm was not used in our scoring of D-motifs.
5.2.3 Motif Scan and Filtering
Candidate MAPK-binding D-motif instances were collected from the human proteome.
Protein sequences were downloaded from the reviewed section of the UniProt database
(The UniProt Consortium 2016). The resulting Human Proteome Database (HPD)
contained 20248 sequences. The HPD was scanned for motif hits with basic pattern








This yielded 87857 hits. Aiming to select the biologically relevant instances, the re-
sulting hits were then filtered as outlined below. Separately, the greater MEF2A
class (uniting the two MEF2A classes) was considered with a merged motif
[RK]x2−4[LIVMP]x[LIV]x[LIVMFP].
Structural Disorder
The estimation of the interaction potential of the selected protein regions was done with
the ANCHOR algorithm, a method trained to recognize binding regions in disordered
protein segments (Mészáros et al. 2009). In linear motif selection, a more permissive
version of ANCHOR can be used; therefore, the default 0.5 cutoff value was lowered in
an adaptive way so that at least 90% of the 47 formerly known D-motifs are retained.
Motif hits were kept only if they overlapped with either region predicted by ANCHOR
with a cutoff of 0.4, or region predicted by ANCHOR using a cutoff of 0.3, but at least
one of the 20 residue flanking regions of the motif hit had to have a sufficiently high
average disorder value (> 0.45) predicted with IUPred (Dosztanyi et al. 2005). As a
result, the number of hits was reduced to 21201.
Intracellular Accessibility
Motif hits were discarded if they resided in proteins that were predicted to have a signal
peptide by SignalP (Petersen et al. 2011) (score > 0.5), and if they were also predicted
not to have a transmembrane region predicted by Phobius (Käll et al. 2007). These
motif hits were predicted to be localized outside of the cell, which is incompatible with
MAPK binding. Alternatively, Phobius was also used to predict signal peptides presence
if SignalP score was sufficiently high (> 0.3). If a motif instance resided in a protein that
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was predicted to have a signal peptide but it also had at least one transmembrane region,
the localization of the motif region was further checked. If it was entirely intracellular,
it was kept, otherwise discarded. This filtering step reduced the number of motif hits to
18952.
Cellular Localization
All hits that were predicted by WoLF PSORT (Horton et al. 2007) to be extracellular
(with score ≥ 25), membrane protein (≥ 25), localized to the endoplasmic reticulum
(≥ 15), or the Golgi (≥ 9) were filtered out, unless they harboured transmembrane
regions, and the region containing the motif was predicted to be localized in the intra-
cellular space. There were 18637 hits remaining after this step.
Structural Accessibility
Motif hits that were determined to reside in Pfam domain (Finn et al. 2014) regions
were discarded. Some hits were also discarded in a manual curation process if they
were located in Pfam Family/Repeat/Motif regions likely to have a stable structure
in isolation. Furthermore, motif occurrences that overlapped with coiled-coil regions
predicted by COILS (Lupas et al. 1991) were removed as well. Finally, there were 14062
motifs remaining for further analysis, including more than 90% of the known positives.
Of these, 298, 382, and 4875 candidate motifs belonged to the classes JIP1, NFAT4, and
greater MEF2A, respectively.
5.2.4 Evaluation of Methods Performance
To evaluate the performance of the methods for classifying the peptides from the different
D-motifs classes as MAPK binders, an artificial negative dataset was created for each of
the JIP1, NFAT4, and greater MEF2A classes. For this purpose, the human proteome
was scanned for motif hits with basic pattern matching for each of the motifs classes
and the hits which were lying in the structured region as defined by Pfam section A
domains were retained, as these motifs were expected not to bind to MAPK. To be
able to perform a comparison using the same set of negatives, the motifs which had
incomplete flank regions due to being close to protein terminus were removed, resulting
in a total of 587, 1995, and 1901 motifs for classes JIP1, NFAT4, and greater MEF2A,
respectively. This last criterion was also applied for the positives dataset, resulting in
947, 381, and 446 motifs for the same classes.
For each of the motifs classes a five-fold cross-validation setting was applied. During
this procedure, each set was split in five approximately equally-sized parts in terms of
number of evolutionarily independent D-motif instances. Four parts were then used for
training and the one remaining part, together with all the motifs from the simulated
negatives for that class, was used for testing, while not allowing motifs from the same
vertebrate ortholog set to be used for both training and testing. This procedure was
repeated 100 times, with the exception of greater MEF2A class, where only 91 com-
binations of training and test dataset were possible for the five-fold cross validation
procedure. AUC, the area under the ROC curve, was calculated using the R package
ROCR (Sing et al. 2005). The ROC curves representing False Positive Rate (FPR) and
True Positive Rate (TPR) values were constructed for thresholds corresponding to the
following three values: i) distance of each motif to the separating hyperplane for the
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SVM models, ii) each motif’s score for the PSSM, and iii) the Viterbi score for each
motif for the HMM models.
5.2.5 Selection and Clustering of Phosphorylation Sites
Candidate human phosphorylation sites with the [ST]P consensus have been collected
from the PhosphoSitePlus database (Hornbeck et al. 2015). Sites where two phospho-
rylation residues follow each other with a maximum distance of five residues between
them (counting from the [ST] site) have been grouped based on that distance into five
separate groups. Each group thus consisted of peptides with two phosphorylation sites
with distances d = 1, . . . , 5 between them and their flanks on both sides, which were of
length min(7, 3 + d). Alignments of proteins embedding these peptides together with
their vertebrate homologs, as reported in the eggNOG database (Jensen et al. 2008),
were then analysed. Only evolutionarily conserved peptides, namely those whose double
phosphorylation sites were conserved in at least one of different species of fish (Latimeria
chalumnae, Tetraodon nigroviridis, Ictalurus punctatus, Cyprinus carpio, Salmo salar,
Oryzias latipes, Takifugu rubripes, Gadus morhua, Osmerus mordax, Oncorhynchus
mykiss, Dicentrarchus labrax, Anoplopoma fimbria, Oreochromis niloticus, Danio rerio)
were kept for further analysis.
Each group was then analysed for similar peptides within it. Specifically,
peptides from the same gene as well as peptides with similar sequences(
Dediti,j
|i| < 0.4, where Dediti,j is the edit distance between peptides i and j
)
which came
from the same Pfam A domain or the same Uniprot entry, have been removed and
represented instead by a consensus sequence of those peptides for the clustering. For all
d = 1, . . . , 5 between the two phosphorylation sites this resulted in a total of 197, 248,
361, 182, and 175 peptides, respectively.






dik ,jk wk, (5.4)
where d is the Euclidean distance between the corresponding entries in the physical-
chemical properties matrix (Venkatarajan and Braun 2001) and wk is the position k
dependent weight. wk is defined as max(1− 110 dist[ST]1 , 1−
1
10 dist[ST]2), where dist[ST]{1,2}
is distance to the first and second phosphorylation site, respectively. This weighting is
used to linearly down-weight the importance of the position as one moves away from the
phosphorylation sites.
The clustering itself was performed using the tight clustering algorithm (Tseng and
Wong 2005) using the R package tightClust (Tseng and Wong 2012). Briefly, tight
clustering is an iterative procedure for performing k-means clustering with a pre-set k
with resampling, with the goal of finding clusters that are most tight (data points within
it tend to cluster together in separate clustering iterations) and stable (tight cluster
candidate which is chosen repetitively for increasing k starting with k0). The core idea
of the method is resampling of data points: at each iteration a pre-set portion of all data
points are randomly left out of the clustering. When the data space tends to be clustered
in a similar way in different such iterations, it is expected to have some structure on top
of random noise. Note that in this approach not all data points get assigned to a specific
cluster in the end, but only those for which this structure is observed.
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Some of the important parameters of the procedure are thus α ∈ [0, 1] (where values
closer to 0 select tighter clusters), β ∈ [0, 1] (where values closer to 1 select more stable
clusters), the resampling iteration number B, and the resampling rate p. Authors of
the tight clustering algorithm identify k0 ∈ [1, ∞] (which is related to expected true
number of clusters, with large k0 values tending to select small tight clusters) as the
most important parameter of the procedure and suggest setting k0 > l + 5, where l is
the expected number of clusters (Tseng and Wong 2012). For the remaining parameters,
authors suggest default values of α = 0.1, β = 0.6, B = 10, and p = 0.7. When testing
performance of clustering for a specific parameter, the rest of the parameters were set
to default values, with the exception of B = 20. Tight clustering was performed for each
group of peptides for cluster sizes l ∈ [2, 15].
The quality of clustering was measured using average of silhouette value s(i) of all
clustered data points i using R package cluster (Maechler et al. 2017):
s(i) =
b(i)− a(i)
max{a(i), b(i)} , (5.5)
where a(i) is the average dissimilarity between i and all the other data points in the same
cluster, and b(i) is the smallest average dissimilarity of i to the points in other clusters.
A silhouette value close to 1 thus indicates presence of a well-ordered structure of the
clusters and −1 indicates a lack thereof. When deciding on which number of clusters to
choose, one typically chooses a number y which gives a local peak of silhouette value,
such that y + 1 has a relatively much lower average silhouette value.
5.3 Results
5.3.1 Prediction Models for D-motif Classes
We employed two techniques to learn from each experimentally verified class of MAPK
binders and their homologs: SVM and PSSM. The same procedure was applied for
testing the performance of those techniques in predicting D-motifs. Namely, 5-fold cross-
validation was performed, selecting 4 folds of D-motifs from that class for training and
1 remaining fold, together with the peptides from Pfam A domains, fitting the D-motif
definition for that class, for testing (see Section 5.2.4).
One-class (also called novelty-detection) SVM (Schölkopf et al. 2000) is a kind of SVM
classifier which uses data from only a single class in its training procedure, during which
it aims to separate that data from the origin with a maximum margin. We built classifier
models for each of peptide classes JIP1, NFAT4, and greater MEF2A. The purpose of
these models is to predict whether an observed test instance of a D-motif peptide is a
member of the class of D-motifs used to train it or not. In the testing phase, peptides
from the founding class are classified together with simulated negatives. We used two
kinds of kernels for comparison of D-motifs: string kernel, which can take D-motifs
directly as input, and RBF kernel, which requires numerical input. Weighted Degree
(WD) (Rätsch and Sonnenburg 2004) and Weighted Degree with Shifts (WDS) (Rätsch
et al. 2005) string kernels were employed, which estimate string similarity based on the
number of matching k-mers between them at fixed (WD) or variable (WDS) starting
positions. The expectation was that the latter, which allows for shifts in positions when
comparing k-mers, would show an improved performance when compared to the former
in the case of greater MEF2A class of D-motifs which has a variable length linker region
between the charged and hydrophobic sites. The results of performance of the models
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in terms of AUC for both kinds of string kernels using k-mers of up to length 4 are
presented in Figure 5.2.
(a) JIP1 (b) NFAT4
(c) Greater MEF2A
Figure 5.2: Performance of SVM classification of D-motifs of JIP1, NFAT4, and greater
MEF2A class in terms of AUC using WD (red) and WDS (blue) kernels of
different degrees.
Comparing WD and WDS kernels, JIP1 and greater MEF2A classes had compara-
ble performance, while the NFAT4 class models with the WD kernel performed better.
This indicated WD kernel as the best overall choice. With respect to the kernel degree,
increasing it improved the performance for classes NFAT4 and greater MEF2A, while
for JIP1 class there was no consistent effect on the performance. Overall all models
for classes JIP1 and greater MEF2A performed well in terms of AUC irrespective of
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Figure 5.3: Performance of SVM models using RBF kernel with physical-chemical
residues encoding in terms of AUC with γ = 1d .
the choice of the type of the string kernel and their degree, and NFAT4 models per-
formed slightly worse, with the mean AUC values for WD kernels 0.94, 0.95, and 0.91
respectively.
For the one-class SVM models with RBF kernel, we converted peptide sequences to
quantitative descriptors as described by (Venkatarajan and Braun 2001). In this five-
dimensional property space, residues that are similar in physical-chemical properties
such as hydrophobicity, size, tendency to occur in α-helices and others, will be more
closely located, whereas residues with large discrepancies in these properties will tend
to have larger distance between them. Usage of such kernel can be seen as a logical
extension of the definitions of D-motifs classes, which are composed of hydrophobic and
charged parts. Figure 5.3 shows the performance of the models built with parameter
γ, which controls the spread of the kernel, set at 1/d, where d is the data dimension.
The average performance for classes JIP1, NFAT4, and greater MEF2A at 0.8, 0.73, and
0.84, respectively, was lower than for SVM models with string kernels and also displayed
higher variance. This variance could be attributed neither to the parameter ν, which sets
the upper bound on the fraction of class outliers and the lower bound on the fraction of
support vectors (Schölkopf et al. 2000), (Figure B.11), nor to the parameter γ (Figure
B.12).
A completely different kind of approach to create a scoring function based on the
peptide classes was to create a PSSM for each class. In this approach, in the training
procedure the homologs could be weighted based on their sequence similarity (see Section
5.2.2). In the testing phase, we calculated AUC for different PSSM score thresholds for
the peptides in the test set (Figure 5.4). With the mean AUC values for classes JIP1,
NFAT4, and greater MEF2A at 0.98, 0.91, and 0.95, respectively, the performance was
very similar to that of SVM with WD kernel, with a slightly better performance for the
JIP1 class.
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Figure 5.4: Performance of PSSM scoring in terms of AUC.
Figure 5.5: Performance of D-Finder scoring in terms of AUC.
An HMM-based predictor of D-motifs crafted for finding JNK-type binding motifs,
called D-finder, has been previously reported (Whisenant et al. 2010). We decided to
evaluate the performance of D-finder with the dataset from our study for comparison
purposes. In their approach, the authors implemented a combined search for D-motif
with the generic consensus, together with a scoring function based on the HMMs trained
using the Viterbi algorithm. Since we already preselected the motifs corresponding to
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different D-motif classes, we excluded the part of the algorithm that used consensus-
based motif search. In the testing phase, we calculated AUC for different score thresholds
for the peptides in the test set (Figure 5.5). With the mean AUC values for classes JIP1,
NFAT4, and greater MEF2A at 0.96, 0.91, and 0.89, respectively, this method displayed
performance comparable to PSSM-based scoring for the NFAT4 class and slightly lower
performance for JIP1 and greater MEF2A classes, while also showing greater variance
for the latter.
Based on these results and because of its performance, simplicity, independence of
parameters, ability to include sequences of different length, and interpretability, we chose
PSSM for scoring of candidate D-motifs in the human proteome.
5.3.2 D-motif Based MAPK Interactome
We now used all motifs from the three classes employed in the performance evaluation
phase, as well as all D-motifs with short flanks due to being close to the N-terminus of
the protein, to create a PSSM for each of the classes. We also used peptides from another
D-motifs class, DCC, to create a separate PSSM. This matrix was trained using only 6
independent D-motif instances. Thus this class was not used in the testing phase, and
was built only for comparison purposes with the other PSSMs. We built sequence logos
based on these matrices for all classes (Figure 5.6). Due to small number of independent
instances of D-motifs used to calculate its PSSM, there is less uncertainty in terms of the
information content in sequence logo of DCC class compared to the others (Figure 5.6a).
Overall there are few cases of conservation outside of the positions predefined by the
regular expressions, which is also in agreement with the fact that the flanking regions
have a small beneficial effect for the performance of the motifs classification (Figure
B.13). One of the exceptions to that is serine or threonine in the position immediately
preceding ϕA in the JIP1 class. An experimentally resolved structure of JIP1–JNK1
complex (Heo et al. 2004) indicates that this amino acid has the ability to form a
hydrogen bond with the underlying arginine side chain of JNK1 (Figure 5.6b). Other
examples are from the greater MEF2A and DCC classes, the first of which includes p38α-
binding, as well as a small fraction of ERK-binding peptides, and the second containing
primarily ERK2 and some of its members also associating with p38α. In these classes a
proline is prefered after ϕB, which, based on the structure of MEF2A peptide with p38α
(C.-I. Chang et al. 2002), can form hydrophobic interactions with the surface of p38α
upon binding (Figure 5.6c).
Having the PSSMs trained on the peptide sequence preferences for all of the classes,
we scanned the human proteome for the presence of motifs of same classes by using reg-
ular expressions. We then filtered the hits based on different structural and localisation
criteria for those motifs as well as their host proteins (see Section Motif Scan and Filter-
ing). The remaining 298, 382, and 4875 hits for the JIP1, NFAT4, and greater MEF2A
classes respectively, were then scored with the corresponding PSSMs. For the purpose of
getting an overview of the kind of biological processes motifs from these classes mediate,
we annotated the top 100 hits from each class based on their UniProt labels, domain
composition, and literature sources.
Out of the three classes examined, the JIP1 type had by far the highest number of
validated hits. Thus, the predictions for this class were deemed most reliable, shedding
some light on the interactome of JNK1 (Figure 5.7). Among the less surprising categories
discovered were the MAPK pathway components themselves, especially at the MAP3K
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(a) Sequence logos generated from PSSMs. In the core motif, the positively charged θ positions
are coloured blue, while the three ϕ hydrophobic contact points are red. Logos generated
using Seq2Logo (Thomsen and Nielsen 2012).
(b) JIP1 peptide with JNK1 complex
structure.
(c) MEF2A peptide with p38α com-
plex structure.
Figure 5.6: Sequence logos for different D-motifs classes and the interactions of JIP1
and MEF2A peptides with MAPKs.
level serving as potential feedback elements. Also expected hits were several transcrip-
tion factors, and other gene expression regulatory systems, or various ubiquitin ligases.
A considerable number of experimentally-tested or predicted JNK-interacting proteins
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have preferentially or exclusively neuronal functions (Figure 5.7b). Interestingly, the ma-
jority of JNK-associating proteins (both experimentally validated and predicted) seem to
be involved in cytoskeletal regulation, as numerous actin-binding or microtubule-binding
proteins, molecular motors as well as small G-protein partners were encountered. Dock-
ing motifs were even found in proteins localized to centrosomes, basal bodies, or those
involved in the formation of primary cilia. Several other high-scoring hits suggest that
JNK is intimately involved in the regulation of endo- and exocytosis. The presence
of insulin signalling pathway components in the lists may also explain many previous
observations on the causative role of JNK in type II diabetes. This kinase is involved
in pathways overactivated by cytokines derived from adipose tissue. JNK1 knockout
mice are also known not to develop type II diabetes induced by obesity (Hirosumi et al.
2002; Sabio et al. 2009). Proteins bearing JIP1-type docking motifs (e.g. MADD, IRS1,
PGC1A) are located in critical points of networks responsible for insulin signalling, and
these are the same pathways that are also targeted by most antidiabetic pharmaceuticals
(Y. H. Lee et al. 2003; Finck and Kelly 2006; Olson et al. 2008; D. Li et al. 2014).
The analysis of the best 100 hits for the NFAT4 class yielded results similar to the
JIP1-type motifs, with some differences (Figure B.14a). In contrast, members of the
greater MEF2A class were markedly dissimilar from those of the JIP1 class. Here,
the proportion of cytoskeletal proteins was minimal, while the fraction of transcription
factors was considerably higher. Proteins involved in other functions related to gene
expression, such as chromatin remodelling or histone methylation, were also present in
high numbers.
When comparing distributions of protein functions, the NFAT4 class appeared to lie
between the two extremes represented by the JIP1 types (mostly cytoplasmatic targets)
and greater MEF2A types (mostly acting in nucleus) (Figure B.14a). The similarity of
NFAT4-type motif-containing proteins to JIP1-type bearing ones is easy to understand:
both primarily interact with JNK1. In certain protein families, one can discover closely
related pairs in which one protein contains a JIP1-type docking motif and the other
contains a likely independently evolved NFAT4-type docking motif (Figure B.14b). On
the other hand, the NFAT4-type motifs are structurally compatible with MEF2A types
(unlike JIP1 types); thus, some of the predicted best binders are shared between the
latter two lists. The dot-blot experiments indeed corroborated that the overlapping
motif definitions result in a naturally overlapping set of interactors for JNK1 and p38α.
(Figure B.14c).
5.3.3 Clustering of Phosphorylation Sites
As a separate part of the study on cellular signalling networks, we analysed known phos-
phorylation sites, such as those targeted by MAPK, to find potential clusters among
them. For this purpose candidate phosphorylation sites have been collected from the
PhosphoSitePlus database (Hornbeck et al. 2015). This database includes sites of human
proteins which had been phosphorylated based on low- and high-throughput experimen-
tal evidence. Among these, phosphorylation sites pairs found in close proximity to each
other (up to 5 residues) were selected together with their flanking regions. For this set
of peptides clustering using the tight clustering approach was performed. Since one can
expect to have a high number of false positives among all the candidate peptides in the
dataset, attempting to cluster all peptides can potentially result in low quality clusters
in terms of them being distorted and difficult to interpret, as well as making the esti-
mation of the true number of clusters problematic. One would instead prefer to find
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(a) Low-level functional classification of JIP1-type motif-bearing proteins.
(b) High-level functional classification of JIP1-type motif-bearing proteins.
Figure 5.7: JNK interactome analysis using 100 highest scoring JIP1-type motifs. Only
categories that contain more than a single protein are shown. Many proteins
are present whose docking motif is already known (blue letters), or was
validated in the dot-blot essays of the present study (red letters).
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(a) d = 1 (b) d = 2
(c) d = 3 (d) d = 4
(e) d = 5
Figure 5.8: The evaluation of clustering performance of phosphorylation site groups of
different distances between the [ST] sites (d) in terms of silhouette value
(solid lines) and proportion of peptides assigned to clusters (dashed lines)
while varying k0 parameter.
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a subset of peptides which form tight clusters and are thus potential candidate sites of
being recognised by a specific downstream protein in the signalling cascade. The tight
clustering approach was designed to solve this problem (Tseng and Wong 2005). This
clustering approach is based on k-means clustering using resampling with the purpose
of finding tight and stable clusters. There are a number of tuning parameters in this
procedure (see Section 5.2.5). Although the Tseng and Wong claim the choice of the
number of clusters k is secondary, k0, which is related to the expected number of true
clusters, is one of the most important parameters. Thus, we performed tight clustering
on the different groups of peptides, separated based on the distance between the two
phosphorylation sites while varying the k0 parameter and the number of target clusters
(Figure 5.8). The low silhouette values, which start at ≈ 0.2 for most of the classes,
suggest a lack of clear groups in the data. As the proportion of peptides assigned to
clusters grows, the silhouette values drop further close to zero, indicating that on average
peptides are as close to other peptides in the cluster as they are to the closest neighbour-
ing cluster. For groups of peptides with distances of 4 or 5 between the phosphorylation
sites, increasing the number of target clusters increases the proportion of data points
assigned only marginally.
We then performed clustering with varying other parameters of the clustering pro-
cedure, namely α, β, and p (Figure B.15). Varying β did not have much effect on
performance neither in terms of silhouette value nor on the proportion of peptides as-
signed to clusters. On the other hand, increasing α and p values had the expected
effect of increasing the fraction of peptides clustered. However, in no tested parameter
combination did the silhouette value raise more than marginally above the 0.2 value.
This suggests the underlying data does not lend itself to structuring using this approach
and/or the adopted distance measure.
5.4 Discussion
Protein kinases often use dedicated domains for substrate recognition. Known examples
include the Src-family tyrosine kinases (SH2 and SH3 domains) (Alexandropoulos and
Baltimore 1996; Pellicena et al. 1998), SPAK/OSR kinases (Vitari et al. 2006) and Polo-
like kinases (Polo-box domains) (K. S. Lee et al. 2014). In other cases, recruitment of
the target proteins is provided by the catalytic domain itself, but by a distinct surface
which is noncontiguous with the catalytic site. This appears to be common among the
so-called cyclin-dependent kinase, MAPK, glycogen synthase kinase, CDC-like kinase
group (CMGC). However, each kinase family uses a different surface with strikingly
different recognition modes. Thus, motifs recognized by GSK3 or SRPKs (Dajani et al.
2003; J. C. K. Ngo et al. 2005) are unrelated to D-motifs or FxFP-motifs of MAPKs, or
to CDK-docking motifs recognized by the cyclin subunit (Lowe et al. 2002). Based on
our results on MAPK-binding D-motifs, it may be anticipated that insights into other
recruitment motif-based systems will greatly contribute to a system-level understanding
of protein kinase-based intracellular signalling networks.
In the current study, we demonstrate that canonical, D-motif-dependent partners of
MAPKs are in fact quite common. However, a number of partners with atypical or
“naturally defective” docking motifs do exist (e.g. MKK3, MKK7, TAB1), and these
are difficult to predict (C.-I. Chang et al. 2002; De Nicola et al. 2013). Often such de-
fective motifs act in a non-autonomous way: these weak elements may be complemented
by additional protein stretches, motifs, or domains (Glatz et al. 2013). Besides, not
all MAPK-binding elements are linear motifs. Folded domains such as the rhodanese
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domain of dual-specificity phosphatases may bind to the same site as intrinsically dis-
ordered docking motifs (Y.-Y. Zhang et al. 2011). MAPKs interactions can also be
mediated by other linear motifs, i.e. the so-called FxFP-motifs (Jacobs et al. 1999;
Fantz et al. 2001; J. Zhang et al. 2003). A considerable number of interactions might
also be indirect, mediated by a third partner.
Nevertheless, directly interacting with a MAPK solely through short linear motifs
appears to be a major and widespread phenomenon in mammals. Although experimental
testing of all putative MAPK D-motifs is challenging to perform, a suggestion can be
made that the fraction of the human proteome that harbours high-scoring D-motifs
may be representative of the full interactomes for three distinct MAPKs. This may be
best captured for JNK1 by the procedure presented in this study. Some of the newly-
identified partners directly fit into the core of MAPK pathways. These include specific
phosphatases as well as MAP3Ks. While there can be little doubt that docking motifs of
phosphatases would be required for MAPK dephosphorylation, the presence of docking
motifs in MAP3Ks is a more intriguing observation. It is probable that phosphorylation
of proteins acting on the MAP3K level (like on MEKK1, MLK1/MLK2, or KSR2) would
allow direct feedback control of MAPK pathways (Flotho et al. 2004).
However, the majority of novel hits appear to lie outside the core MAPK pathway
module, and these are probably simple downstream elements (i.e. substrates). Most of
the novel proteins are expected to be either direct MAPK substrates or scaffold proteins
(i.e. enabling phosphorylation of indirect MAPK substrates through protein complexes).
The wide distribution of D-motifs in a functionally diverse set of proteins explains
how MAPKs can regulate such a broad spectrum of physiological processes. Previously,
their specific regulatory roles were often attributed to single target proteins. For exam-
ple, the role of JNK in axonal growth was attributed to the JNK–JIP1 interaction, and
the association of JNK with diabetes was attempted to be explained by the JNK1–IRS1
interaction alone (Y. H. Lee et al. 2003; Dajas-Bailador et al. 2008). In contrast, results
from the current study imply that these interactions may only be two examples of a
substantially more complex protein network, and JNK (as all MAPKs) connects to its
targeted physiological systems by a large number of direct interactions. While individual
connections might not be stable (especially in the evolutionary sense), multiple specific
linkages could provide the key mechanism for a robust and adaptable physiological reg-
ulation.
Surprisingly, many of the newly implied MAPK partners have a restricted expression
pattern enabling fine-tuned regulation in specialized tissues. Because of the latter phe-
nomenon, a great deal of these interactions are unlikely to be discovered by large-scale
protein–protein interaction screens. Easy-to-handle cell lines and mass-spectrometry-
based analyses provide a powerful tool, but not for proteins that are only expressed in
special, differentiated tissues (e.g. AAKG2, which is only abundant in cardiomyocytes)
or restricted to certain embryonic developmental stages (e.g. DCX is almost exclusively
expressed in developing neuroblasts) (Lang et al. 2000; Brown et al. 2003). Here, a
modelling-driven interactome search is the most suitable tool to fill in the gaps in our
knowledge. In addition, a reliable sequence-based prediction procedure sets the stage
for an easy examination on how MAPK signalling partners changed over time during
evolution.
In the study of the human proteome phosphorylated sites, we analysed peptides with
pairs of [ST]P sites in close proximity to each other, which are targeted by proline-
directed kinases (such as MAPKs). The purpose was to find groups which would be
recognised by specific downstream proteins in the signalling cascade. Despite the fact
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that the tight clustering approach that we employed is supposed to select the part
of the data that forms tight and stable clusters, we could not observe much of such
structure in our set of peptides. This can potentially indicate the need to modify the
hypothesis with regards to specifics of the motifs recognised by the downstream protein
or the recognition mechanism. Alternatively one could narrow down the hypothesis by
assuming that the recognition mechanism is used only by select proteins and to search
for these groups within clusters formed. The performance of tight clustering approach
itself is dependent on a number of different tuning parameters, with the number of
expected clusters being one of them. Tuning these parameters is of course problematic
in the context of unsupervised learning where there is no target variable. Finally, one





In this work, sequence- and structure-based approaches were applied to analyse different
protein–protein and protein–inhibitor interaction systems. Despite the differing contexts
of those systems, the replication of a virus and the eukaryotic signalling network, being
disparate in numerous facets, both direct (Greenway et al. 1996; Yang and Gabuzda
1998; Yang and Gabuzda 1999; Gupta et al. 2011; Dochi et al. 2014) and indirect
(Schrager et al. 2002; Toschi et al. 2006) interaction has been suggested between some
of the main actors of these systems, HIV proteins and MAPKs. In fact, MAPK was
the first protein kinase originating from cells which was detected within HIV particles
(Cartier et al. 1997; Jacqué et al. 1998; Giroud et al. 2011). Similarly, despite the use of
sequence- and structure-based methods being restricted in the context of this work to
MAPK signalling network and the HIV protease drug resistance, respectively, studying
these individual problems also benefited from both of these approaches. For example,
the analysis of the MAPK interaction partners through D-motifs is largely sequence-
based, but it has doubtlessly benefited from the premise of the project to use structural
considerations to divide the D-motifs based on their different binding modes to MAPKs.
We see potential future directions of expanding these projects both on the basis of
principles of methodological approaches predominantly used in those projects so far and
those from the other category. This chapter concludes the dissertation by summarizing
its key developments and results and provides a perspective for future work in the area.
6.1 Conclusions
In the study of HIV protease, the major focus was a diverse set of RAMs in combination
with different PIs. The goal was to see whether the experimental measurements of the
resistance, both in terms of free energy of binding of the inhibitor, ∆G, and phenotyp-
ical resistance assays, RF, can be reproduced by the computational techniques based
on MD simulations as well as to understand the underlying resistance mechanisms. It
is first shown on a dataset of ten complexes that the change of the free energy of the
inhibitor binding upon mutation, ∆∆G, calculated using alchemical calculations corre-
lates well with the experimental measurements. It was observed that explicit probing
of alternative protonation states of the active site of the protease contributes to this
accuracy, in addition to enabling us to select the most likely protonation state of the
complex. It is then shown for two datasets with RF measurements where multiple pro-
teases share the same sequence but have different inhibitor bound, totalling seventeen
different complexes, that those RF measurements can be in most cases reproduced from
the calculated ∆∆G values for the same complex. Comparison of RF and ∆∆G values
for the same mutation also provided insights into whether the change in resistance is
predominantly a result in drug binding affinity or of a change in the catalytic activity
of the protease. We correlate these observations with the presence or lack of specific
secondary mutations. Finally, the analysis of the MD simulations underlying the ∆∆G
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estimations reveals various effects of mutations on the protease structure and its inter-
actions with the inhibitor. For RAMs found in the active site, the effect of mutations
is mostly through changes in direct protein–inhibitor interactions; for RAMs in distant
sites, protein–inhibitor interactions are also affected by mutation, but the underlying
mechanisms are more complex and include displacements of specific side chains, changes
in hydrogen bond network of the protease, differences in correlated movements of the
residues and/or structural rearrangements of the protein.
In the study of the specificity of D-motifs in the MAPK signalling we made several im-
portant observations regarding the MAPK interactome. After observing that D-motifs
acquire distinct binding modes when bound to a specific MAPK, we split known and ex-
perimentally validated human D-motifs into separate classes. Together with the related
vertebrate D-motifs, peptides from each class could then be used to train different kinds
of predictive models, which could successfully distinguish them from a dataset of sim-
ulated negatives. Models based on PSSMs trained on different motif classes performed
best in our comparison and were used to score D-motifs in the human proteome with
the following annotation of the top-scoring hits. This gave us insight into the different
physiological processes, in which proteins that embed these D-motifs participate, as well
as into the differences between proteins with D-motifs from different classes in terms of
their cellular localization. In this study, we also analysed different kind of linear binding
motifs which are phosphorylated, among other proteins, by MAPKs. We performed clus-
tering on pairs of phosphorylated [ST]P sites in short distance to each other, aiming at
finding tight clusters of motifs potentially indicative of being recognition sites of down-
stream proteins in the signalling cascades. Despite using a clustering approach which
selectively clustered only those data points that tended to form clusters with each other,
the goal of finding a cohesive structure among motifs with pairs of phosphorylation sites
proved difficult to achieve.
6.2 Outlook
The current work presents a successful application of alchemical methods based on MD
simulations for an accurate estimation of the effects of different HIV protease major
RAMs, both inside and outside of the active site, on the enzyme resistance towards
various drugs. This allowed to gain valuable insights into the resistance mechanisms of
HIV protease at the molecular level. However, there is still a big gap in understanding
the molecular details of the resistance of a number of major RAMs towards different
inhibitors, including, e.g. I84V, which was part of the current study in predicting RF
based on free energy estimates, let alone numerous minor RAMs. Understanding the
underlying molecular phenomena could potentially provide important insights into the
HIV drug resistance, as well as a possibility to transfer this knowledge to treatment of
other viruses, and for drug design.
The current study also provided an insight into the balance between the most im-
portant effects of primary and secondary mutations, namely free energy of the inhibitor
binding and catalytic activity, two phenomena that both contribute to the observed
RFs. Statistical analysis of co-occurring mutations in the HIV protease, which already
is being explored in connection to the analysis of resistance of this protein (Hoffman
et al. 2003), combined with free energy and virological assay resistance studies, might
reveal further cases of this interplay. On the other hand, finding mutations which, while
selected on their own through, e.g. drug pressure, do not co-occur, or mutations which
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are resistance-inducing and sensitizing towards different drugs, such as some of those dis-
cussed in this study, might offer an advantage directly applicable for patient treatment.
Overall, unlike statistical learning approaches in optimizing the drug therapy based
on clinical data, which have found a way in application in clinical practice (Lengauer
et al. 2014), statistical mechanics-based approaches on evaluating drug resistance are
of course a few steps away from such immediate application. As demonstrated in the
present study, the problem setting can also be very specific to each molecular complex
under consideration. There is however continuous progress in both hardware, in terms of
computational power, and software, which, e.g. now allows to automate the tedious and
technical knowledge-demanding task of preparing the hybrid structures for alchemical
simulations (Gapsys et al. 2014). With such advancements, one can envisage a wider
application of molecular mechanics-based approaches for free energy estimations, which
provides the advantage of having a solid physical basis and offering a high accuracy,
even for large scale mutational studies.
There are many prospective avenues for further work on MAPK signalling network.
We take part in an ongoing project to identify peptides with multiple phosphorylation
sites indicative of specific biological function, with experiments being conducted by our
collaborators to verify peptides from individual clusters as potentially binding to F-
box/WD repeat-containing protein 7 (FBW7) as a part of MAPK signalling. The basic
motif required for binding, which includes the phosphorylation sites, potentially needs
refining to find the underlying pattern essential for signal transduction in the network.
Alchemical methods for estimating free binding energy could be applied to supplement
the experiments verifying candidate peptide binders. Specifically, closed thermodynamic
cycles could be constructed to test how changes of amino acids in specific positions af-
fect the free binding energy of that peptide to the target protein. The same approach
could of course be used for the D-motifs binding to MAPKs to further refine consensus
D-motifs sequences as preferred by different MAPKs. Since MAPKs are involved in var-
ious widely spread human diseases, they are natural pharmaceutical targets. Alchemical
approaches could also be employed here for evaluating different candidate drugs, tar-
geting both the active site and its other interaction sites, such as the D-motifs binding
site. The questions posed in the current dissertation on the minimal required motifs
and interaction mechanisms in the MAPK signalling network are undoubtedly crucial





EC50 Effective Concentration corresponding to the
half-maximal response
IC50 Inhibitor Concentration required to reduce
enzymatic reaction activity by 50%






BAR Bennet Acceptance Ratio
CCD Charged-Coupled Device
CFT Crooks Fluctuation Theorem
CRF Circulating Recombinant Form
cryo-ET cryo Electron Cryotomography




FDA U.S. Food and Drug Administration
FEP Free Energy Perturbation
FPR False Positive Rate
FPV Fosamprenavir
HIV-1 Human Immunodeficiency Virus type 1
HIV-2 Human Immunodeficiency Virus type 2
HIVDR Human Immunodeficiency Virus Drug Resistance
HMM Hidden Markov Model
IDV Indinavir
83
84 List of Abbreviations
INI Integrase Strand-Transfer Inhibitor






MM/GBSA Molecular Mechanics/Generalized Born Surface
Area




NMR Nuclear Magnetic Resonance
NNRTI Non-Nucleoside Reverse-Transcriptase Inhibitor
NRTI Nucleotide or Nucleoside Reverse-Transcriptase
Inhibitor
PB Poisson–Boltzmann
PBMC Peripheral Blood Mononuclear Cell
PCA Principal Component Analysis










RBF Radial Basis Function




SIV Simian Immunodeficiency Virus
SQV Saquinavir
SVM Support Vector Machine
TI Thermodynamics Integration
TPR True Positive Rate
TPV Tiprananavir
List of Abbreviations 85
WD Weighted Degree
WDS Weighted Degree with Shifts
WHO World Health Organization
86 List of Genes, Transcripts, Proteins, and Complexes
List of Genes, Transcripts, Proteins, and Complexes
AAKG2 5’-AMP-activated protein kinase subunit gamma-2
AFT2 activating transcription factor 2
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G
CA capsid
CCR5 C-C chemokine receptor type 5
CD4 cluster of differentiation 4
CDK cyclin-dependant kinase
CMGC cyclin-dependent kinase, MAPK, glycogen synthase kinase, CDC-like
kinase group
CXCR4 C-X-C chemokine receptor type 4
DCC deleted in colorectal carcinoma
DCX neuronal migration protein doublecortin
Elk-1 ETS domain-containing protein Elk-1
env envelope
ERK extracellular signal-regulated kinase
ERK1 mitogen-activated protein kinase 3
ERK2 mitogen-activated protein kinase 1
ERK3 mitogen-activated protein kinase 6
ERK4 mitogen-activated protein kinase 4
ERK5 mitogen-activated protein kinase 7
ERK7 mitogen-activated protein kinase 15




GSK3 glycogen synthase kinase 3
HePTP protein tyrosine phosphatase non-receptor type 7
IN integrase
IRS1 insulin receptor substrate 1
JIP1 c-Jun-amino-terminal kinase-interacting protein 1, also called
MAPK8IP1 or JNK1 interacting protein 1
JNK c-Jun N-terminal kinase
JNK1 mitogen-activated protein kinase 8
JNK2 mitogen-activated protein kinase 9
JNK3 mitogen-activated protein kinase 10
KSR2 kinase suppressor of ras 2
LTR long terminal repeat
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MA matrix
MADD MAPK-activating death domain protein
MAP2K mitogen-activated protein kinase kinase
MAP3K mitogen-activated protein kinase kinase kinase
MAPK mitogen-activated protein kinase
MEF2A myocyte-specific enhancer factor 2A
MEKK1 MAP2K kinase 1
MKK3 dual specificity mitogen-activated protein kinase kinase 3
MKK4 dual specificity mitogen-activated protein kinase kinase 4
MKK7 dual specificity mitogen-activated protein kinase kinase 7
MKP MAPK phosphatase
MLK1 MAP2K kinase 9
MLK2 MAP2K kinase 10
NC nucleocapsid
Nef negative regulatory factor
NFAT4 nuclear factor of activated T-cells 4
NLK nemo-like kinase
OSR oxidative stress-responsive kinase
p38 p38 mitogen-activated protein kinase
p38α mitogen-activated protein kinase 14
p53 tumor protein p53
PDK1 phosphoinositide-dependent protein kinase 1
PDZ post synaptic density protein (PSD95), Drosophila disc large tumor
suppressor (Dlg1), and zonula occludens-1 protein (zo-1)-domain
PGC1A peroxisome proliferator-activated receptor gamma coactivator 1-alpha
pol polymerase
PR protease
Rev regulator of expression of virion proteins
RT reverse transcriptase
SH2 Src homology 2
SH3 Src homology 3
SPAK sterile20 related proline-alanine-rich kinase
SRPK serine/threonine-protein kinase
TAB1 MKK7-interacting protein 1
Tat trans-activator of transcription
Vif virion infectivity factor
Vpr viral protein R




Refers to the unbound state of the protein.
AUC
Refers to the Area Under ROC curve.
CD groove
Common Docking groove. Refers to a negatively charged region on the the MAPK
surface, which, together with hydrophobic docking groove, is where the D-motifs
bind.
D-motif
Docking motif. Refers to a short linear peptide sequence which facilitates the
interaction between the protein, in which it is found, and MAPK by binding to
the docking groove of the later.
holo
Refers to the ligand-bound state of the protein.
homolog
A gene related to a another gene by descent from a common ancestor.
HXB2
Name of a nucleatide sequence of HIV-1 group M subtype B which is comonly
used as a reference wildtype sequence of HIV-1. Numbering of nucleotide and
amino acid positions in this sequence can be found at https://www.hiv.lanl.
gov/content/sequence/HIV/REVIEWS/HXB2.html
hydrophobic docking groove
Refers to a hydrophobic region on the the MAPK surface, which, together with
CD groove, is the binding site for D-motifs.
NPT
Refers to isothermal-isobaric ensemble, where number of particles N, pressure P,
and temperature T are constant.
ortholog
A homolog that is the result of a speciation event.
paralog
A homolog that is the result of a duplication event.
RFR
Describes RF ratio between two mutant sequences (as compared to wildtype
HXB2).
ROC curve
Receiver Operating Characteristic curve describes performance of a binary classi-
fyer at different decision thresholds in terms of TPR and FPR.
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Table B.1: Selected reference protonation states for dataset 1. If alternative inhibitor
orientation states A and B with the same occupancy were present in the
original structure, state A was always selected, with the exception of 3NU3,
where state B was selected, resulting in opposite orientations of the inhibitor
APV with respect to the two monomers when comparing 1HPV and 3NU3.
Structure Inhibitor Reference protonated ∆∆Gprot
aspartic acid
5T8H APV D25 1.46 ± 0.19
5E5J DRV D25′ 2.36 ± 0.44
5E5K DRV D25 2.32 ± 0.36
2ZYE KNI-272 D25 1.01 ± 0.30
Table B.2: Free energy change upon switching the proton from the reference active site
aspartic acid as found in structure to the active site aspartic acid on the
opposite protease monomer.
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Mutation Isolate Reference
M46I wildtype 71V-11, A71V-7, Bru-A71V-3 (Colonno et al. 2004)mutant P372 (Petropoulos et al. 2000)
I84V wildtype JGP-M1C (Prado et al. 2002)mutant JGP-M2C, JGP-M2R (Prado et al. 2002)
N88S wildtype RZ27 (IDV), RZ28 (FPV) (Ziermann et al. 2000)mutant RZ22 (IDV), RZ-L4 (FPV) (Ziermann et al. 2000)
Table B.3: Isolates, for which measurements of RF were used in dataset 2 as reported
in HIVdb, and references to the studies where RF measurements were per-
formed.
(a) M46I APV (b) M46I IDV
(c) I84V APV (d) M84I IDV
Figure B.1: Calculated RFR distributions and experimental estimates for dataset 2. p
designates the proportion of RFcalcR at least as extreme as RF
exp
R compared
to <RFcalcR >. Nota bene: in case of APV, RF
exp
R measurements are for its
prodrug FPV.
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(e) I84V LPV (f) I84V SQV
(g) N88S APV (h) N88S IDV
Figure B.1: Calculated RFR distributions and experimental estimates for dataset 2. p
designates the proportion of RFcalcR at least as extreme as RF
exp
R compared
to <RFcalcR >. Nota bene: in case of APV, RF
exp
R measurements are for its
prodrug FPV (cont.)
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(a) FB15 ATV (b) FB15 SQV
(c) GH9 ATV (d) GH9 SQV
(e) RU1 ATV (f) RU1 LPV
Figure B.2: Calculated RFR distributions and experimental estimates for dataset 3. p





(g) iZ2 ATV (h) iZ2 IDV
(i) iZ2 LPV
Figure B.2: Calculated RFR distributions and experimental estimates for dataset 3. p
designates the proportion of RFcalcR at least as extreme as RF
exp
R compared
to <RFcalcR > (cont.)
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(a) I50V ATV (b) I50V LPV
(c) I50V TPV (d) I50V APV
Figure B.3: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes for dataset 1. Only residues, for which
the difference between the wildtype and the mutant complexes is higher
than the propagated error and its absolute value higher than 0.1 kcal/mol
are shown.
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(e) I50V IDV (f) I50V* APV
(g) I50V* IDV (h) G48V SQV (i) G48V/L90M SQV
Figure B.3: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes for dataset 1. Only residues, for which
the difference between the wildtype and the mutant complexes is higher
than the propagated error and its absolute value higher than 0.1 kcal/mol
are shown (cont.)
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(j) L90M
SQV
(k) I50V/A71V ATV (l) I50V/A71V APV
Figure B.3: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes for dataset 1. Only residues, for which
the difference between the wildtype and the mutant complexes is higher
than the propagated error and its absolute value higher than 0.1 kcal/mol
are shown (cont.)
(a) FB15 ATV (b) FB15 SQV
Figure B.4: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes for dataset 3. Only residues, for which
the difference between the wildtype and the mutant complexes is higher
than the propagated error and its absolute value higher than 0.1 kcal/mol
are shown.
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(c) GH9 ATV (d) GH9 SQV
(e) RU1 ATV (f) RU1 LPV
Figure B.4: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes for dataset 3. Only residues, for which
the difference between the wildtype and the mutant complexes is higher
than the propagated error and its absolute value higher than 0.1 kcal/mol
are shown.
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(g) iZ2 ATV (h) iZ2 IDV
(i) iZ2 LPV
Figure B.4: Energy differences of non-bonded interaction between protein and inhibitor
in wildtype and mutant complexes for dataset 3. Only residues, for which
the difference between the wildtype and the mutant complexes is higher
than the propagated error and its absolute value higher than 0.1 kcal/mol
are shown (cont.)
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(a) I50V ATV (b) I50V LPV
(c) I50V TPV (d) I50V APV
(e) I50V IDV (f) I50V* APV
(g) I50V* IDV (h) G48V SQV
(i) G48V/L90M SQV (j) L90M SQV
Figure B.5: Correlation between predicted and true labels in the PLS models for the
protein backbone trajectories from dataset 1 in cross validation for back-
bone (black), protein (green), side chain (blue), N+Cα+Cβ+CD/SG (cyan),
Cα+Cβ (magenta), and inhibitor (red) heavy atoms.
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(a) I50V ATV (b) I50V LPV







Figure B.6: Interpolation between the extremes of the PLS models for the corresponding
complexes for dataset 1. Blue-to-magenta bands correspond to the interpo-
lation along the mode which relates the true label of simulation, wildtype
or mutant, to the underlying differences in protein motions.
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(a) ATV (b) LPV
(c) TPV (d) APV
(e) IDV (f) APV*
(g) IDV* (h) SQV
Figure B.7: Mutual information mapped onto the wildtype protease structures for
dataset 1. Cylinders connecting residues represent differences in mutual
information between those residues in apo and holo wildtype simulations,
with the width of the cylinder proportional to the difference, red indicat-
ing higher mutual information in the holo complexes and blue in the apo
complexes. This corresponds to the degree to which residue pairs exhibit
differences in the correlation of their motions.
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(a) χ1 (b) χ2
Figure B.8: Distribution of I84 side chain χ angles in WT (rose) and L90M (blue) mutant
proteases in complex with SQV simulations from dataset 1.
(a) Motion between the extremes along PC1
(b) Simulation snapshots distribution along
PC1 and PC2. Green-to-red corresponds
to lower-to-higher population density of
snapshots
Figure B.9: PCA of wildtype, G48V, G48V/L90M, and L90M protease complexes with
SQV from dataset 1. Blue-to-magenta in (a) corresponds to minimum-to-
maximum along the first principal component (PC) in (b).
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APV M46I D25′ −1.86 ± 0.23 −2.32 ± 0.21
IDV M46I D25 1.15 ± 0.27 0.53 ± 0.45
APV I84V D25′ −1.67 ± 0.25 −0.31 ± 0.27
IDV I84V D25 1.67 ± 0.44 1.29 ± 0.38
LPV I84V D25′ −0.6 ± 0.35 −1.33 ± 0.3
SQV I84V D25 1.03 ± 0.19 2.04 ± 0.27
APV N88S D25 2.23 ± 0.29 −0.16 ± 0.24
IDV N88S D25 2.22 ± 0.51 1.42 ± 0.45
Table B.4: Change of the free energy of inhibitor binding upon switching the proton
from the reference protonated active site residue to the active site residue
on the opposite subunit for dataset 2. ± shows bootstrap error estimate, all
values in kcal/mol.




ATV FB15 D25′ −1.17 ± 0.31 −2.08 ± 0.36
SQV FB15 D25 −0.08 ± 0.25 0.4 ± 0.37
ATV GH9 D25′ −0.13 ± 0.21 −1.23 ± 0.32
SQV GH9 D25 0.45 ± 0.21 −0.08 ± 0.31
ATV RU1 D25′ −4.21 ± 0.38 −1.76 ± 0.47
LPV RU1 D25′ −1.41 ± 0.32 −0.75 ± 0.37
ATV iZ2 D25 −0.82 ± 0.34 −1.25 ± 0.4
IDV iZ2 D25′ −0.95 ± 0.44 1.43 ± 0.31
LPV iZ2 D25 0.56 ± 0.27 0.5 ± 0.75
Table B.5: Change of the free energy of inhibitor binding upon switching the proton
from the reference protonated active site residue to the active site residue
on the opposite subunit for dataset 3. ± shows bootstrap error estimate, all
values in kcal/mol.
Inhibitor and mutation ATV LPV TPV APV IDV APV IDV SQV SQV SQV Overall
combination I50V I50V I50V I50V I50V I50V* I50V* G48V G48V/L90M L90M Mean
Jaccard Index 0.05 0.19 0.53 0.16 0.44 0.24 0.27 0.33 0.35 0.28 0.28
Table B.6: Jaccard index estimates between two difference matrices of mutual informa-
tion for dataset 1: the first is apo vs. holo simulations of the wildtype protein
and the second is for wildtype vs. mutant simulations for the holo protein.
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(a) FB15 ATV (b) FB15 SQV
(c) GH9 ATV (d) GH9 SQV
(e) RU1 ATV (f) RU1 LPV







Figure B.10: Interpolation between the extremes of the PLS models for the correspond-
ing complexes for dataset 3. Blue-to-magenta bands correspond to the
interpolation along the mode as represented as cartoon for backbone and
as sticks residues 30, 45, and 58. Mutated residue 76 is not part of the
model and represented here as gray dash.
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Residues Inhibitor N88 S88 N88′ S88′
D30/D30′ APV 0.005 ± 2 × 10
−4 0.61 ± 0.05 5 × 10−4 ± 3 × 10−7 0.66 ± 0.12
IDV 2 × 10−4 ± 2 × 10−7 0.22 ± 0.008 0.001 ± 2 × 10−6 0.55 ± 0.08
T31/T31′ APV 1.28 ± 0.004 0.21 ± 0.03 1.56 ± 0.003 0.13 ± 0.04IDV 1.26 ± 0.007 0.47 ± 0.03 1.35 ± 0.008 0.27 ± 0.04
T74/T74′ APV 0.8 ± 0.003 3 × 10
−4 ± 2 × 10−7 0.85 ± 0.001 2 × 10−4 ± 2 × 10−7
IDV 0.71 ± 0.001 2 × 10−4 ± 2 × 10−7 0.79 ± 0.001 3 × 10−4 ± 9 × 10−7
Table B.7: Average hydrogen bonds number between residues D30, T31, and T74 and
N88 and S88 for wildtype and mutant complexes, respectively, in dataset
2. Columns 3 and 4 of the table corresponds to hydrogen bonds within
monomer A of protease and columns 5 and 6 of the table corresponds to
hydrogen bonds within monomer B of protease (residues marked with prime
symbol). ± indicates standard error of bond frequency across independent
simulations.
Inhibitor Mutation ∆∆Gexp ∆∆Gtotal ∆∆Gtheor
APV I50V* 2.03 1.21(0.82) −5.07(7.1)a
IDV I50V* 2.33 0.32(2.01) −4.40(6.73)a
APV I50V* 2.03 1.21(0.82) 1.49(0.54)a
IDV I50V* 2.33 0.32(2.01) 2.89(0.56)a
SQV G48V 2.78 2.66(0.12) 3.73(0.71)b
SQV L90M 1.60 0.09(1.51) 3.49(2.13)b
SQV G48V/L90M 4.03 6.03(2) 4.4(0.37)b
Table B.8: Experimental estimates of the change of the free energy of inhibitor binding
upon mutation used the current study, ∆∆Gexp, theoretical estimates from
the current study, ∆∆Gtotal, and computational predictions for the same mu-
tations from the literature, ∆∆Gtheor, with unsigned error in the parenthesis.
a taken from (R. Duan et al. 2015) and b from (Stoica et al. 2008). All values
in kcal/mol.
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(a) JIP1 (b) NFAT4
(c) Greater MEF2A
Figure B.11: Performance of SVM models using RBF kernel with physical-chemical
residues encoding for classification of MAPK D-motifs in terms of AUC
for different ν parameter values.
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(a) JIP1 (b) NFAT4
(c) Greater MEF2A
Figure B.12: Performance of SVM models using RBF kernel with physical-chemical
residues encoding for classification of MAPK D-motifs in terms of AUC
for different kernel width γ = 1d f values.
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(a) JIP1 class (b) NFAT4 class
(c) Greater MEF2A class
Figure B.13: Performance of the PSSM-based classification using D-motifs of different
flank lengths.
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(a) Comparison of functional grouping of hits among the 100 highest scoring JIP1, NFAT4 or
greater MEF2A type motifs.
(b) Selected examples of protein families in which one member carries a JIP1-type motif, but
another closely related member has an NFAT4-type motif instead. Shown example motifs
are either high-ranking predictions or were experimentally validated.
(c) Experimental proof for the suggested overlap between JNK1 and p38α partners. The upper
numbers in this diagram represent the number of motifs (of either NFAT4 or greater MEF2A
types) that were tested as positive in the dot-blot arrays. The lower row of numbers shows
the numbers that selectively interact with JNK1 (blue), p38α (yellow) or with both (green)
in the dot-blot arrays. For each case, a few characteristic examples are also given below.
Figure B.14: Comparisons of highest scoring 100 hits for JIP1, NFAT4, and greater
MEF2A type motifs.
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(a) d = 1 (b) d = 1
(c) d = 1 (d) d = 2
(e) d = 2 (f) d = 2
Figure B.15: The evaluation of performance of clustering of phosphorlytion site groups
with different distances between the [ST] sites (d) in terms of silhouette
value (solid lines) and proportion of peptides assigned to clusters (dashed
lines) while varying separately α, β, and p parameters.
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(g) d = 3 (h) d = 3
(i) d = 3 (j) d = 4
(k) d = 4 (l) d = 4
Figure B.15: The evaluation of performance of clustering of phosphorlytion site groups
with different distances between the [ST] sites (d) in terms of silhouette
value (solid lines) and proportion of peptides assigned to clusters (dashed
lines) while varying separately α, β, and p parameters (cont.)
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(m) d = 5 (n) d = 5
(o) d = 5
Figure B.15: The evaluation of performance of clustering of phosphorlytion site groups
with different distances between the [ST] sites (d) in terms of silhouette
value (solid lines) and proportion of peptides assigned to clusters (dashed
lines) while varying separately α, β, and p parameters (cont.)
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